AU2002219873A1 - Medical device for delivery of a biologically active material to a lumen - Google Patents
Medical device for delivery of a biologically active material to a lumenInfo
- Publication number
- AU2002219873A1 AU2002219873A1 AU2002219873A AU2002219873A AU2002219873A1 AU 2002219873 A1 AU2002219873 A1 AU 2002219873A1 AU 2002219873 A AU2002219873 A AU 2002219873A AU 2002219873 A AU2002219873 A AU 2002219873A AU 2002219873 A1 AU2002219873 A1 AU 2002219873A1
- Authority
- AU
- Australia
- Prior art keywords
- balloon
- micro
- needles
- active material
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011149 active material Substances 0.000 title claims description 138
- 239000011148 porous material Substances 0.000 claims description 41
- 239000012530 fluid Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 30
- 238000004891 communication Methods 0.000 claims description 28
- 239000000463 material Substances 0.000 claims description 17
- 239000000232 Lipid Bilayer Substances 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 230000008081 blood perfusion Effects 0.000 claims description 2
- 230000000644 propagated effect Effects 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 230000002045 lasting effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 23
- 229920000642 polymer Polymers 0.000 description 22
- 239000007787 solid Substances 0.000 description 18
- -1 polyethylene Polymers 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000007788 liquid Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 7
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 239000010703 silicon Substances 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 229920002873 Polyethylenimine Polymers 0.000 description 5
- 206010065647 Systemic leakage Diseases 0.000 description 5
- 229910052681 coesite Inorganic materials 0.000 description 5
- 229910052906 cristobalite Inorganic materials 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229910052682 stishovite Inorganic materials 0.000 description 5
- 229910052905 tridymite Inorganic materials 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 239000004593 Epoxy Substances 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 2
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000004019 antithrombin Chemical class 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000009713 electroplating Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229920002120 photoresistant polymer Polymers 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical compound ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- VNDNKFJKUBLYQB-UHFFFAOYSA-N 2-(4-amino-6-chloro-5-oxohexyl)guanidine Chemical compound ClCC(=O)C(N)CCCN=C(N)N VNDNKFJKUBLYQB-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229940123011 Growth factor receptor antagonist Drugs 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 1
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 description 1
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 1
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NTUPOKHATNSWCY-JYJNAYRXSA-N Phe-Pro-Arg Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=CC=C1 NTUPOKHATNSWCY-JYJNAYRXSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007772 electroless plating Methods 0.000 description 1
- 238000006056 electrooxidation reaction Methods 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000407 epitaxy Methods 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920009441 perflouroethylene propylene Polymers 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 238000005240 physical vapour deposition Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001849 poly(hydroxybutyrate-co-valerate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000001797 sucrose acetate isobutyrate Substances 0.000 description 1
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 description 1
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000003803 thymidine kinase inhibitor Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000001039 wet etching Methods 0.000 description 1
Description
MEDICAL DEVICE FOR DELIVERY OF A BIOLOGICALLY ACTIVE MATERIAL TO A LUMEN
5 FIELD OF THE INVENTION
This invention relates generally to medical devices and methods for delivering a biologically active material to a desired location within the body of a patient. More particularly, the invention is directed to medical devices having a catheter and a balloon with a plurality of micro-needles at its outer surface for delivering a biologically , rs active material to a body lumen. Additionally, the invention is directed to medical devices having a catheter, a balloon and a sheath surrounding the balloon. Also, the invention is directed to medical devices having a catheter, a balloon and a Shockwave generator for delivery of biologically active materials.
j 5 BACKGROUND OF THE INVENTION
When a disease is localized to a particular part of the body, in particular a body lumen, such as, without limitation, a blood vessel, direct administration of biologically active materials for the treatment of the disease may be more preferred than systemic administration. Systemic admimstration requires larger amounts and/or higher n concentrations of the biologically active materials because of inefficiencies associated with the indirect delivery of such materials to the afflicted area. Also, systemic administration may cause side effects which may not be a problem when the biologically active material is locally administered.
However, such localized delivery of biologically active materials to a body jr lumen is difficult since body lumens are involved in the transport of body fluids, which tend to carry the biologically active material away from the afflicted area. Thus, there is a need for devices and methods for the localized delivery of biologically active materials to afflicted tissue, especially body lumens.
A number of devices for delivering biologically active materials to body Q lumens or vessels involve the use of catheters having expandable portions, such as a balloon, disposed on the catheter. To overcome the problem that the delivered biologically active material is washed away from the applied area by the blood-flow, there are generally two kinds of prior art balloon catheters: one kind is a balloon catheter which temporarily occludes blood-flow and infuses a biologically active material to the occluded area, and the
- c other kind is a balloon catheter which directly administers the biologically active material to a vessel wall by the use of macro-needles. However, the former still has the problem of
systemic leakage around the balloon, allowing for systemic distribution of the biologically active material. On the other hand, although the latter type of balloon catheters do not cause significant systemic leakage of the biologically active material, because of the large size of the macro-needles used to inject the biologically active material into the tissue, there is still back-leakage at the needle track. Also, the large size of the needles cause damage in the tissue of the vessel wall. Thus, the prior art balloon catheters cannot deliver a biologically active material quickly and accurately to a wall of body lumen without causing damage in the body lumen tissue and/or systemic leakage.
In addition, rapid advances in DNA technologies have increased the necessity for a device or method which realizes more accurate and uniform delivery of genetic materials. Therefore, there is still a need for devices and methods which cause minimum tissue damage while ensuring accurate and uniform localized delivery of biologically active materials including genetic materials to body lumens.
SUMMARY OF THE INVENTION
These and other objectives are accomplished by the present invention. To achieve the aforementioned objectives, we have invented a medical apparatus and a method for delivery of a biologically active material to a surface of a body lumen.
The apparatus for delivery of biologically active materials of the invention comprises a catheter and a balloon having micro-needles. h an embodiment of the invention, the apparatus comprises a catheter, a balloon, with a biologically active material disposed on an outer surface of the balloon, and micro-needles disposed upon the outer surface of the balloon. The micro-needles contact a body lumen as the balloon is expanded, and the biologically active material is delivered into the body lumen. The biologically active material can be delivered by fluid convection along the outer surface of the micro-needles. Alternatively, biologically active material can, instead of being disposed on the outer balloon surface, be expelled from an inner compartment of the balloon through pores in the outer balloon surface. The balloon is optionally surrounded by a sheath.
In another embodiment of the invention, the apparatus comprises a catheter having at least one lumen in fluid communication with an internal compartment of the balloon, and micro-needles having a lumen in fluid communication with the compartment, wherein the micro-needles are disposed upon an outer surface of the balloon. The micro-needles contact a body lumen as the balloon is expanded, and the biologically active material is delivered to the body lumen through the micro-needle lumen. The balloon is optionally surrounded by a sheath.
Further, another embodiment of the apparatus of the invention compπses a catheter, a balloon disposed upon the catheter, and a Shockwave generator for delivery of a biologically active material.
Moreover, in another embodiment, the apparatus of the invention comprises a catheter, a balloon having micro-needles disposed upon or within an outer surface of the balloon, and a triggering source for rupturing the micro-needles. The micro-needles are ruptured by the triggering source, which can be a Shockwave, and a biologically active material is delivered through the micro-needles to an afflicted area of a body lumen.
The present invention also includes a method for delivering a biologically active material to a body lumen, h one embodiment, the method is carried out by inserting a catheter with a balloon disposed thereon into a body lumen. The balloon has micro- needles disposed upon or within its outer surface. Once the catheter is inserted, the balloon is inflated so that the micro-needles contact the surface of the body lumen. The biologically active material is then delivered to the surface of the body lumen.
In another embodiment, the method of the invention involves inserting a catheter having a balloon disposed upon it into a body lumen. The balloon is inflated to contact a body lumen. A Shockwave is then applied to the afflicted area of the body lumen to allow delivery of the biologically active material into the body lumen.
DESCRIPTION OF THE FIGURES
Figure 1 illustrates a configuration of an embodiment of a balloon catheter of the invention.
Figures 2A and 2B depict cross-sectional views along the longitudinal axis of embodiments of a balloon catheter of the invention, wherein hollow micro-needles with apertures are disposed upon a plate which is disposed on a balloon surface or within the balloon wall. The catheter has a lumen for containing the biologically active material and another lumen for inflating the balloon. Details of the micro-needles are shown in the enlarged portion of the balloon.
Figure 3 depicts a cross-sectional view along the longitudinal axis of another embodiment of a balloon catheter of the invention, wherein solid micro-needles, i.e., micro- needles without lumens, are disposed upon a plate which is disposed upon a balloon surface or within the balloon wall. The outer surface of the balloon is coated with a polymer containing a biologically active material. Details of the micro-needles are shown in the enlarged portion of the balloon.
Figures 4A and 4B depict a cross-sectional view along the longitudinal axis of another embodiment of a balloon catheter of the invention, wherein solid micro-needles
wall and the micro-needles project through a porous outer surface of the balloon. In Figure 4A, the micro-needles are disposed upon a porous plate, and the plate is attached to the inner surface of the balloon wall. In Figure 4B, the micro-needles may be mounted on a solid plate and the solid plate is attached to the inner surface of the balloon wall. Details of the micro-needles are shown in the enlarged portions of the balloon.
Figures 5 A and 5B depict cross-sectional views of another embodiment of a balloon catheter of the invention, wherein a sheath surrounds a balloon having hollow micro-needles. In Figure 5A, the balloon is in its deflated state. In Figure 5B, the balloon is in its inflated state. Details of the micro-needles are shown in the enlarged portions of the balloon.
Figure 6A depicts a cross-sectional view along the longitudinal axis of another embodiment of a balloon catheter of the invention in its deflated state, wherein a sheath surrounds a balloon having solid micro-needles. Figure 6B depicts a cross-sectional view of the same embodiment which is cut along the line I-I in Figure 6 A. A portion of the Figure 6B is enlarged to Figure 6B'. Figure 6C shows the same portion as in Figure 6B' and the balloon is in its inflated state.
Figures 7A and 7B depict cross-sectional views along the longitudinal axis of a portion of another embodiment of a balloon catheter of the invention, wherein a sheath surrounds a balloon having micro-needles. In Figure 7A, the balloon is in deflated state, and in Figure 7B, the balloon is in its inflated state.
Figures 8A and 8B depict cross-sectional views along the longitudinal axis of other embodiments of balloon catheters of the invention where a Shockwave generator is used to deliver the biologically active material.
Figures 9A, 9B and 9C each depict an embodiment of a micro-needle which is capable of being ruptured.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The medical apparatus suitable for the present invention include those having at least an inflatable portion such as a balloon. The term "balloon" is defined as an inflatable bag-like object made of a balloon wall. The balloon wall may be made of one or more layers. The balloon may contain one or more internal walls in addition to the balloon wall. Also, the balloon can have more than one compartment.
A configuration of an embodiment of an apparatus of the present invention is illustrated in Figure 1. The embodiment includes a catheter 12 which has a proximal end 14 and distal end 16 and includes a guide wire and a lumen for inflation (both not shown in Figure 1). A balloon 10 with micro-needles (not shown) disposed upon its outer surface is
a Shockwave generator 13 disposed upon the proximal portion 14 of "the catheter 12". Once the catheter is introduced into a body lumen in a manner known to the skilled artisan, the balloon is positioned to a targeted area in the body lumen and then inflated to contact a surface of the body lumen in a way known in the art. After a biologically active material is delivered, the balloon is deflated and removed.
Figures 2A and 2B show two embodiments of the present invention. A balloon 20 A in Figure 2A is disposed upon a catheter 29 having a guidewire 28. The balloon 20A is made of a balloon wall 27 having an inner and outer surface and has an internal wall 23, an inflation compartment 26, and an internal compartment 25a surrounded by the balloon wall 27 and the internal wall 23. A plate 102, having pores 102a and a plurality of micro-needles 21 disposed upon it, is positioned on the inner surface 27a of the balloon wall 27. The micro-needles 21 project through the balloon wall 27 and are disposed on the outer surface of the balloon 27b. It should be noted that the micro-needles do not have to be actually resting on the outer surface in order to be considered as being disposed thereon. As long as the micro-needles protrude through or from the surface, they are considered as being disposed upon the surface. The micro-needles 21 have an aperture 24 and a lumen 22. The lumen 22 is aligned with the pores 102a such that the lumen 22 is in fluid communication with the interior compartment 25a of the balloon 20A. The interior compartment 25a can be in fluid communication with a lumen 29b of the catheter 29.
The term "micro-needle" is a term of art. Generally, a "micro-needle" is construed as a needle having a diameter at most about 100 μm, preferably about 10 μm or less and a length at most about 1 mm. The micro-needles applicable to this invention include hollow ones 21 such as those in Figure 2A. The term "hollow" means having one or more lumen(s) 22 running through the interior of the micro-needle 21, wherein fluid and/or solid materials can pass through the lumen(s) 22. These hollow micro-needles 21 can preferably have an aperture 24 connected to the lumen 22 of the micro-needle 21. The term "aperture" means an opening in the outer surface of the micro-needle 21 which are sufficiently large to allow passage of fluid and/or solid materials out of the micro-needles. The aperture can be at the tip of the micro-needles or located at other places in the micro-needle outer surface, hi other embodiments as discussed below, the micro-needles can be solid or capable of being ruptured.
In the embodiment shown in Figure 2A, the balloon 20A is inflated by infusing a liquid or gas into the inflation compartment 26 of the balloon 20A using inflation lumen 29a of the catheter 29. As the balloon 20A is inflated, the micro-needles 21 contact a surface of the body lumen, and a biologically active material located in the interior balloon compartment 25a is delivered through the micro-needle lumens 22 and aperture 24 to the
systemic leakage. After the delivery is completed, the balloon 20A is deflated and removed from the body lumen. In other embodiments, the lumen 29b for the biologically active material and the inflation lumen 29a can be the same; and/or the inflation compartment 26 and the interior compartment 25a containing the biologically active material can be the same.
Figure 2B shows another embodiment, a balloon 20B, which is similar to the balloon 20A in Figure 2A, except that the interior compartment 25b is not connected to a catheter lumen. In this embodiment, the interior compartment 25b contains the biologically active material, and expansion of the inflation compartment 26 will squeeze the biologically active material out of the interior compartment 25b through the micro-needles 21 into the body lumen surface.
Another embodiment of the present invention is shown in Figure 3. A balloon 30 is made of balloon wall 37, and the balloon wall is made of an outer layer 37b and an inner layer 37a. In this embodiment, a plurality of solid micro-needles 31 are disposed upon a plate 302 which is disposed between the outer layer 37b and the inner layer 37a. The micro-needles project through the outer layer 37b and are disposed on an outer surface of the balloon. The micro-needles can also be hollow in other embodiments. The outer surface of the balloon 30 is coated with a polymer containing a biologically active material 32. The balloon 30 is inflated by infusing a liquid or gas into an inflation compartment 33 using an inflation lumen 39a of the catheter 39 having a guidewire 38. The needles 31 pierce the body lumen and create micro-pores or nano-pores, i.e., spaces of the size of the micro-needle, in the body lumen. The biologically active material contained in the coating 32 is squeezed by the balloon 30 and forced into or allowed to seep into the micro- or nano-pores created by the micro-needles. After a predetermined time, the balloon 30 is deflated and removed from the body lumen. The time during which the balloon is inflated is determined by the type of body lumen tissue, the biologically active material used, carrier material or coating if used and the size and number of needles. For example, if the body lumen is a coronary artery, the time is generally between about 5 seconds and about 2 minutes, preferably between about 10 and about 30 seconds.
Figure 4A shows another embodiment of an apparatus of the present invention. A plurality of solid micro-needles 41 are disposed upon a porous plate 402, which is disposed on a porous balloon wall 47 of the balloon 40A. In some embodiments, the needles can be hollow. The porous plate 402 has a plurality of pores 44, and the porous balloon wall 47 has a plurality of pores 42. The balloon 40A also includes an interior compartment 45 defined by an internal wall 43. The balloon 40A of this embodiment is inflated in a body lumen by inserting a liquid or gas into an inflation compartment 46 using
micro-needles 41 contact a surface of the body lumen piercing the surface and create micro- or nano-pores in the surface. Then, a biologically active material, which is placed into the interior compartment 45 of the balloon 40A using a first catheter lumen 49b, is expelled from the interior compartment 45 through the pores 44 of the plate 402 and the pores 42 of the balloon wall 47. The biologically active material is delivered into the micro- or nano- pores created by the micro-needles 41. After the biologically active material is delivered, the balloon is deflated and removed from the body lumen.
In the other embodiments, the interior compartment 45 is not in fluid communication with catheter lumen 49b. Instead, the interior compartment 45 contains the biologically active material, and expansion of the inflation compartment 46 will squeeze the biologically active material out of the interior compartment 45 tlirough the pores 42 and pores 44.
Figure 4B shows another embodiment of an apparatus of the present invention. A plurality of solid micro-needles 41 are disposed upon a plate 403. The plate 403 is disposed between an outer layer 47b and an inner layer 47a of an balloon wall 47 of a balloon 40B. The outer layer 47b has a plurality of pores 42. The micro-needles 41 are positioned such that they project through the outer layer 47b and are disposed on an outer surface of the balloon. The plate 403 and the outer layer 47b define a compartment 45, which contains a biologically active material. The biologically active material is placed into the compartment 45 using a first catheter lumen 49b. The balloon 40B of this embodiment is inflated in a body lumen by inserting a liquid or gas into an inflation compartment 46 using an inflation lumen 49a of the catheter 49 having a guidewire 48. Upon inflation, the micro-needles 41 contact a surface of the body lumen piercing the surface and create micro- or nano-pores in the surface. The biologically active material is expelled from the pores 42 and is delivered into the micro- or nano-pores created by the micro-needles 41. After the biologically active material is delivered, the balloon is deflated and removed from the body lumen.
Another embodiment of the apparatus of the present invention is shown in Figures 5 A and 5B. A balloon 50 is in its deflated state in Figure 5 A and in its inflated state in Figure 5B. The balloon 50 has generally the same structure as that shown in Figures 2A and 2B except that it is surrounded by a sheath 52. The sheath is used to protect both the micro-needles and the surface of a body lumen, while the balloon with micro-needles are being positioned in or withdrawn from the body lumen. The sheath can also prevent the biologically active material from being inadvertently delivered during catheter placement or withdrawal. A plurality of micro-needles, in this case hollow micro-needles 54 having apertures, are disposed upon a plate 502, which is disposed on the inner surface 57a of a
the balloon wall 57 and an interior wall 53. The micro-needles 54 project tlirough the balloon wall 57 and are disposed upon an outer surface of the balloon. The sheath 52 has a plurality of ports or openings 51 through which the micro-needles 54 are able to project. The balloon 50 is inflated by infusing a liquid or gas into the inflation compartment 56 of the balloon 50 using an inflation lumen 59a of the catheter 59 having a guidewire 58. As the balloon 50 is inflated, the balloon wall 57 contacts the sheath 52 and the micro-needles 54 project out through the ports 51 of the sheath 52. The sheath 52 may expand by being pushed outwardly by the balloon 50 as in Figure 5B. The micro-needles 54 contact a surface of the body lumen piercing the surface. A biologically active material, which is placed into the interior compartment 55 using a first catheter lumen 59b, is delivered, quickly and accurately without systemic leakage, through the micro-needles 54 into the body lumen. After the injection is completed, the balloon 50 is deflated, and the sheath 52 may collapse, or return to its original state. In other embodiments, a similar type of sheath can be used with a balloon catheter shown in Figure 3. In another embodiment, the sheath 52 may not have any ports and is removed after the balloon 50 has been placed at the target area of the body lumen where the biologically active material is to be deliver.
Figure 6A is a cross-sectional view of a balloon 60 along its longitudinal axis, and Figure 6B is a cross-sectional view of the balloon 60 along line I-I in Figure 6A. A portion of Figure 6B is enlarged and referred to as Figure 6B'. Figure 6C shows the same portion of the balloon as in Figure 6B' and in its inflated state. The balloon 60 has generally the same structure as that shown in Figures 5 A and 5B except that it has solid micro-needles 64 instead of micro-needles having lumens and does not have an interior compartment. A plurality of micro-needles 64 are disposed upon a plate 602 which is disposed on the outer surface 67a of a balloon wall 67. The balloon 60 comprises an inflation compartment 66. When the balloon 60 is in its deflated state, the micro-needles 64 lay along the outer surface 67a of the balloon wall 60 and are covered by a sheath 62 as shown in Figure 6B'. The sheath 62 has a plurality of ports or openings 61.
The balloon 60 is inflated by placing a fluid into the inflation compartment 66 of the balloon 60 using an inflation lumen 69a of the catheter 69 having a guidewire 68. As the balloon 60 is inflated, the micro-needles 64 become erect such that they protrude from an outer surface 67a of the balloon 60. Upon inflation of the balloon 60, the outer surface 67a contacts the sheath 62 and the micro-needles 64 project out through the ports 61 of the sheath 62 as shown in Figure 6C. The sheath 62 may expand by being pushed outwardly by the balloon 60. A biologically active material may be placed on the outer surface 67a of the balloon 60 (not shown). When the micro-needles 64 contact a surface of the body lumen, piercing the surface and create micro- or nano-pores in the body lumen, the
created by the micro-needles 64. After a predetermined time, the balloon 60 is deflated, and the sheath 62 may collapse, or return to its original state, and those are removed from the body lumen.
In other embodiments, the balloon 60 may have an internal compartment for delivering a biologically active material, and either the micro-needles 64 have lumens or the balloon 60 is porous to allow delivery of the biologically active material.
A portion of another embodiment of the apparatus of the present invention is shown in Figures 7 A and 7B. A balloon 77 is in its deflated state in Figure 7 A and in its inflated state in Figure 7B. Since the balloon 77 has generally the same structure as that shown in Figures 5A and 5B, the figures do not show the entire balloon, hi this embodiment, the sheath 72 surrounding the balloon 72 has a plurality of micro-needle- channels 71a for guiding the micro-needles 74 through the ports 71 of the sheath 72. The length of the channel 71 is shorter than that of the micro-needles 74, and the internal diameter of the channel 71 is larger than the external diameter of the micro-needles 74. As shown in Figure 7A, when the balloon 77 is deflated, only a part of the micro-needles 74 are surrounded by the channels 71a. As the balloon 77 is inflated, the micro-needles 74 are guided by the channels 71a through the ports 71. When the balloon 77 is in its most inflated state, as shown in Figure 7B, the tips of the micro-needles 74 project out through the ports 71 and contact the surface of the body lumen piercing its surface.
Figures 8 A and 8B depict cross-sectional views of another embodiment of the invention in which a Shockwave source or a Shockwave generator is employed. In the embodiment shown in Figure 8 A, the balloon 80A is disposed upon a distal portion of a catheter 89 having a guidewire 88. The balloon 80A has an inflation compartment 86 and an interior compartment 85 for containing a fluid. The inflation compartment is in fluid communication with an inflation lumen 89a of the catheter 89 and the interior compartment 85 is in fluid communication with a first catheter lumen 89b. A Shockwave source (not shown in Figure 8 A; see Figure 1, number 13) can be disposed upon a proximal portion of the catheter 89. The biologically active material is contained in a polymer coating 81 on the outer surface 87a of the balloon 80A. When the balloon 80A is positioned and inflated to contact a surface of the body lumen, a Shockwave is generated by the source and is propagated through the first catheter lumen 89b and through the interior compartment 85. The Shockwave disrupts the cell lipid bilayer of the cells at the body lumen and can simultaneously create a compressive force which delivers the biologically active material through the disrupted cell lipid bilayer into cell cytoplasm. A Shockwave is a wave formed of a traveling zone of pressure within a fluid.
In Figure 8B, the balloon 80B is disposed upon a distal portion of a catheter
interior compartment 85. The inflation compartment"8ό" is in fluid communication with an inflation lumen 89a of the catheter 89 and the interior compartment 85 is in fluid communication with a first lumen 89b of the catheter. The interior compartment 85 contains a biologically active material that is preferably suspended or dissolved in a fluid. Preferably, the balloon wall 87 contains a plurality of pores 82. When the balloon 80B is positioned and inflated to contact a surface of the body lumen, the biologically active material is infused into the interior compartment 85 and slowly expelled from pores 82 in the balloon wall 87. A Shockwave is generated by a Shockwave generator and propagates through the first lumen 89b and the biologically active material in the interior compartment 85. The Shockwave disrupts the cell lipid bilayer of the cells in the body lumen and also creates a compressed force which delivers the biologically active material through the disrupted cell lipid bilayer into cell cytoplasm.
Further, in another embodiment, a balloon catheter, for either expelling a biologically active material through pores in a balloon wall or delivering the biologically active material contained in a polymer coated on the outer surface of the balloon, is inserted in a body lumen of an afflicted area. Then, a Shockwave source generates a Shockwave from outside the patient's body, wherein the Shockwave is focused on a body lumen. The Shockwave disrupts the cell lipid bilayer of the cells in the body lumen and also creates a compression force which delivers the biologically active material through the disrupted cell lipid bilayer into cell cytoplasm.
The following is a more detailed description of suitable materials and methods useful in producing and using the apparatus of the invention.
One can use the apparatus of the present invention to apply a biologically active material to a surface of a body lumen.
The term "biologically active material" encompasses therapeutic agents, such as drugs, and also genetic materials and biological materials. The genetic materials mean DNA or RNA, including, without limitation, of DNA/RNA encoding a useful protein stated below, intended to be inserted into a human body including viral vectors and non-viral vectors. Viral vectors include adenoviruses, gutted adenoviruses, adeno-associated virus, retroviruses, alpha virus (Semliki Forest, Sindbis, etc.), lentiviruses, herpes simplex virus, ex vivo modified cells (e.g., stem cells, fibroblasts, myoblasts, satellite cells, pericytes, cardiomyocytes, sketetal myocytes, macrophage), replication competent viruses (e.g., ONYX-015), and hybrid vectors. Non- viral vectors include artificial chromosomes and mini-chromosomes, plasmid DNA vectors (e.g., pCOR), cationic polymers (e.g., polyethyleneimine, polyethyleneimine (PEI)) graft copolymers (e.g., polyether-PEI and polyethylene oxide-PEI), neutral polymers PNP, SP1017 (SUPRATEK), lipids or
the protein transduction domain (PTD). The biological materials include cells, yeasts, bacteria, proteins, peptides, cytokines and hormones. Examples for peptides and proteins include growth factors (FGF, FGF-1, FGF-2, NEGF, Endotherial Mitogenic Growth Factors, and epidermal growth factors, transforming growth factor α and β, platelet derived endothelial growth factor, platelet derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin like growth factor ), transcription factors, proteinkinases, CD inhibitors, thymidine kinase, and bone morphogenic proteins (BMP's), such as BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Ngr-1), BMP-7 (OP-1), BMP-8. BMP-9, BMP-10, BMP- 11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Currently preferred BMP's are BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Cells can be of human origin (autologous or allogeneic) or from an animal source (xenogeneic), genetically engineered, if desired, to deliver proteins of interest at the transplant site. The delivery media can be formulated as needed to maintain cell function and viability. Cells include whole bone marrow, bone marrow derived mono-nuclear cells, progenitor cells (e.g., endothelial progentitor cells) stem cells (e.g., mesenchymal, hematopoietic, neuronal), pluripotent stem cells, fibroblasts, macrophage, and satellite cells.
Biologically active material also includes non-genetic therapeutic agents, such as:
• anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone);
• anti-proliferative agents such as enoxaprin, angiopeptin, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid, amlodipine and doxazosin;
• anti-inflammatory agents such as glucocorticoids, betamethasone, dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine;
• antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, methotrexate, azathioprine, adriamycin and mutamycin; endostatin, angiostatin and thymidine kinase inhibitors, taxol and its analogs or derivatives;
• anesthetic agents such as lidocaine, bupivacaine, and ropivacaine; anti-coagulants such as D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin anticodies, anti-platelet receptor antibodies, aspirin (aspirin is also classified as an analgesic, antipyretic and anti-inflammatory drug),
dipyridamole, protamine, hirudin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; vascular cell growth promotors such as growth factors, Vascular Endothelial Growth
Factors (FEGF, all types including NEGF-2), growth factor receptors, transcriptional activators, and translational promotors; vascular cell growth inhibitors such as antiproliferative agents, growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vasoactive mechanisms; anti-oxidants, such as probucol; antibiotic agents, such as penicillin, cefoxitin, oxacillin, tobranycin angiogenic substances, such as acidic and basic fibrobrast growth factors, estrogen including estradiol (E2), estriol (E3) and 17-Beta Estradiol; and drugs for heart failure, such as digoxin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors including captopril and enalopril.
The biologically active material can be used with (a) biologically non-active material(s) including a solvent, a carrier or an excipient, such as sucrose acetate isobutyrate (SABER™ commercially available from SBS) ethanol, n-methyl pymolidone, dimethyl sulfoxide, benzyl benxoate and benzyl acetate.
The device of the present invention can be used to apply the biologically active material to any surface of a body lumen where a catheter can be inserted. Such body lumen include blood vessels, urinary tract, coronary vasculature, esophagus, trachea, colon, and biliary tract.
The present invention is generally directed to a balloon catheter device that includes an elongate, flexible catheter which extends along a longitudinal axis between a proximal end and distal end. The catheter includes an outer wall which surrounds an interior passageway, or a lumen which extends along the longitudinal axis from the proximal end. Any catheter of the type generally in use can be used for the present invention. The catheter can be extruded from a polymer, such as polyethylene, polyamides, polyimides, PEBAX or similar material.
The catheter of the present invention may have more than one lumen including one for liquid or gas for inflating the balloon and one or more lumen(s) for
dissolved or suspended in a fluid such as a liquid or gas. Also, the catheter can have one or more lumen(s) for guide wire(s). The guide wire(s) may extend through the whole catheter shank and balloon. Alternatively, a guide wire may be disposed outside the catheter and extends through an inner lumen only in the area of the balloon as shown in U.S. Patent No. 5,154,725. Also, the catheter can include a lumen for blood perfusion.
A balloon is disposed coaxially about the catheter on the distal portion of the catheter. A material for the balloon of the type generally in use can be employed for the present invention. Non-limiting examples for the balloon material include polyethylene terephthalate (PET), polyamides, polyimides, PNC, polyurethanes and similar materials. In one embodiment of the present invention, the balloon has a porous balloon wall, i.e., the balloon has a plurality of pores through which the biologically active materials can travel to the place of delivery or afflicted area.
In another embodiment, the balloon outer surface has a polymer coating containing a biologically active material. Hydrogel polymers are often used to contain the biologically active material and are disclosed in U.S. Patent No. 5,304,121, PCT publication WO95/03083 and U.S. Patent No. 5,120,322 which are incorporated by reference. However, a non-hydrogel, such as proteins, synthetic and natural polymers, lipids, and micro-spheres, can be also used for the present invention. The coating may be formed by an appropriate method known in the art.
The balloons of the present invention can have one or more compartment(s) including an inflation compartment. When the balloon has a coating of a polymer containing a biologically active material on its outer surface, the balloon may have only an inflation compartment, i.e., a compartment for containing liquid or gas for inflating the balloon. Also, when the balloon is used to contain the biologically active material, the balloon may have only one compartment which is for both containing the inflation gas/liquid for inflation of the balloon and containing the biologically active material. When the balloon has more than one compartment, one of the compartments can be used for inflation of the balloon, and the other(s) can be used for containing the biologically active material. The balloon compartment for inflation is preferably located closer to the center of the balloon than the compartment(s) for containing the biologically active material which is/are preferably located directly inside of the balloon wall or is in fluid communication with either pores or micro-needles in the balloon. However, the compartment for containing the biologically active material does not have to necessarily surround the whole inflation compartment.
In one embodiment of the present invention, the balloon includes a plurality of micro-needles. As shown in Figures 2A, 2B, 3, 4A, 4B, 5A, 5B, 6A -C, 7A and 7B the
stated above, the term "micro-needle" is a term of art, and generally construed as a needle of a diameter at most 100 μm and of a length at most 1 mm. An appropriate size of the micro-needles depends on the thickness of the balloon, the size of body lumen where the balloon catheter is introduced, how deep the targeted site is located from the top of the body lumen surface, and also the size of the biologically active material to be delivered. Generally, the outer diameter of the micro-needles is between about 10 nm and about 100 μm, preferably about 10 μm and below. The length of the micro-needles is typically between about 1 μm and about 1 mm, preferably about 10 μm and about 500 μm, more preferably between about 30 μm and about 200 μm. The minute size of the micro-needles will permit inter-cell penetration at controllable depths minimizing tissue damages. Furthermore, the balloon can include micro-needles of different sizes, i.e., diameters and/or length.
The micro-needles maybe solid or porous, and hollow or non-hollow, i.e., solid. The term "porous" means having sufficient pores or voids where fluid and/or solid materials can pass through. The hollow micro-needle may have a tip having an aperture connected to a lumen through the micro-needle or a porous tip having a plurality of pores where at least one lumen running through the micro-needle is connected to one of the pores. The porous tips allow radial distribution of biologically active material from an individual micro-needle.
The micro-needles can be ruptured. When a micro-needle is capable of being ruptured, the micro-needle preferably has at least one weak spot which is easily broken to give an opening without creating any debris. Figures 9A, 9B and 9C each depict a cross-sectional view along the longitudinal axis of embodiments of micro-needles capable of being ruptured. The micro-needles 90A, 90B and 90C, have an interior lumen 92. The wall of the needle 94 has at least one weak spot 96a, 96b and 96c which breaks upon application of a triggering energy or triggering source to the micro-needles. Upon rupture, an opening in fluid communication with the needle lumen 92 is formed. In Figures 9A and 9C, the weak spots 96a and 96c are spots where a part of the needle wall 94 is thinner than the rest of the needle wall. In Figure 9B, the weak spot 96b is a tip where the needle wall 94 is made of a material which is weaker than that from which the rest of the needle wall is made, h another embodiment, micro-needles have an aperture which is weakly sealed with a quickly dissolving, bioabsorbable material.
The rupturing of the micro-needles can be triggered by various sources, such as a Shockwave, ultrasound energy, radio-frequency, light, temperature and other energy conducting sources, such as those used for detaching the coils disclosed in U.S. Patent No. 5,569,245 to Guglielmi, which are incorporated by reference. Examples of suitable
5,725494 to Brisken, PCT publications WO00/16704, WO00/18468, WO00/00095, WO00/07508 and WO99/33391, which are all incorporated by reference. The triggering source, such as a Shockwave, generates the needed pressure to rupture the micro-needle tips and to expel a dose of the biologically active material at sufficient velocity to penetrate the cell lipid bilayer of the cells of the body lumen.
The micro-needles capable of being ruptured may be made from a bioabsorbable material, such as poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), ρoly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycotic acid), poily(D, L-lactic acid), poly(glycotic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-ester) (e.g. PEO/PLA), polyalkylene oxalates, polyphosphazenes and biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid.
When the micro-needles are non-hollow, i.e., solid, the micro-needles may have gutters on their exterior surface along their longitudinal axis. The biologically active material can travel along the gutter to the afflicted area by capillary action. A biologically active material is either contained in a coating on the surface of the balloon or expelled from the pores in the balloon wall, and is delivered into the micro- or nano-pores, i.e., the punctures created by the micro-needles. Also, hollow micro-needles and solid micro-needles can be used together in a single balloon.
The micro-needles of the present invention can be made from a number of appropriate materials, such as metals, ceramics, semiconductors, organics, polymers and composites. Preferred materials are stainless steel, nickel, iron, tin, chromium, copper, gold, titanium, alloys of these or other metals, glass, silicon, silicon dioxide and polymers, such as PET, polyurethane, PNC, polyamides, polycarbonates, polyethylene, and high- density UPE. Bioabsorbable polymers are preferable in case the micro-needles are broken and left in a body lumen or tissue.
The micro-needles are micro-fabricated by processes known to the skilled artisans, e.g., etching techniques, such as photoresist, wet, and dry removal; electroplating and electroless plating; diffusion processes, such as boron, phosphorus, arsenic, and antimony diffusion; film deposition, such as evaporation, sputtering, chemical vapor deposition (CND), epitaxy, electroplating, screen printing, lamination stereolithography, laser machining, and laser ablation; lithography; thermal oxidation of silicon. Those methods are explained in greater detail in PCT publication WO99/64580 and Micromechanical Devices for Intravascular Drug Dlivery, Michael L. Reed, Journal of
Pharmaceutical Sciences, vol. 87, no. 11, (Nov. 1998), 1387-1394 which are incorporated by reference.
For example, metal micro-needles disposed on a plate can be made by physical vapor deposition of appropriate metal layers on solid needle forms made by silicon, by embossing, or by injection molding. The silicon solid needle form can be made, e.g., by using thermal oxidation of silicon, a wafer is thermally oxidized to grow a thin layer of SiO2, and then, the SiO2 layer is patterned by photolithography. When the SiO2 layer is immersed in an aqueous solution of potassium hydroxide, the wafer surface not covered with SiO2 is etched, and the areas covered with SiO2 becomes the solid micro-needles.
Particularly, methods for making hollow micro-needles disposed on a plate is also known in the art (see WO99/64580). Examples for such methods are a micromold plating method:
(1) A photo-defined mold is first produced by, e.g., spin casting a thick layer, about 150 μm, of an epoxy onto a substrate, such as glass or silicon, that has been coated with a thin sacrificial layer (e.g., copper laminate), typically about 10 to 50 nm thick. A plurality of cylindrical holes are then photolithographically defined through the epoxy layer.
(2) The sacrificial layer, is partially removed at the bottom of the cylindrical holes in the photoresist by e.g., wet etching.
(3) A seed layer, such as Ti/Cu/Ti (e.g., 30nm/200nm/30nm) is conformally DC sputter-deposited onto the upper surface of the epoxy mold and onto the side walls of the cylindrical holes. The seed layer should be electrically isolated from the substrate.
(4) One or more electroplatable metals or alloys, such as Ni, Ni, Fe, Au, Cu, or Ti are electroplated onto the seed layer.
(5) The surrounding epoxy is removed, leaving a plate having hollow micro-needles disposed upon it.
Tapered hollow micro-needles can be made in the same way by making a tapered mold e.g., by using a mold-insert or laser-ablated mold. Porous micro-needles can be made either by etching a porous material or rendered solid micro-needles porous, for example, by means of electrochemical oxidation.
Various methods can be used to displace the plate upon which the micro-needles are disposed, to the balloon. In one embodiment, the plate is secured to the inner surface of the balloon wall in a manner such that the plate and balloon wall will move as a single unit upon expansion. Furthermore, a balloon having micro-needles can be prepared by, first forming a balloon by a conventional method and then attaching plates
using heat or chemical treatment, the plate can be secured to the balloon by covering it with another balloon or a sheath, h one embodiment, a second balloon is formed over a first balloon on which a plate with micro-needles is attached, and the micro-needles project through the second balloon, hi another embodiment, the plate is secured to the inner surface of the balloon wall so that the micro-needles are retracted when the balloon is deflated and will protrude through the balloon wall when the balloon is inflated. The balloon wall can be punctured by the micro-needles or it can have openings for micro-needles to protrude through. Also, the plate can be located within the balloon wall, such that it is sandwich between two layers of material that make up the balloon wall.
Alternatively, a balloon having micro-needles can be prepared from a polymer sheet having micro-needles. A sheet having micro-needles can be prepared by attaching a plate having micro-needles to a polymer sheet by, e.g., heat or chemical treatment or using an adhesive prior to formation of a balloon. In one embodiment, instead of heat or chemical treatment, the plate having micro-needles can be pressed to the polymer sheet so that the micro-needles project through the polymer sheet. The plate may be warmed so that the micro-needles can easily project through the polymer sheet. In another embodiment a second layer of balloon wall material is attached to the underside (i.e., side without needles) of the plate. Once the plate is attached to the polymer sheet, the sheet is folded to form a balloon by a conventional method.
The micro-needles can be oriented perpendicular or at an angle to the outer balloon surface. Hollow micro-needles may be in fluid communication with an internal compartment of the balloon. The micro-needles may be distributed uniformly within the area of the balloon surface which contacts the body lumen when the balloon is expanded. Alternatively, the micro-needles can be disposed upon a limited area of the balloon surface, such as its one half side or its center. The number of the micro-needles distributed in a given area of the balloon depends on the targeted tissue. Generally, about one micro-needle per ten (10) cells is preferred. Typically, the number of the micro-needles is more than about ten (10) per cm2, preferably between about lxlO2 and about lxlO6, more preferably between about lxlO3 and about lxlO5 per cm2. The numerous micro-needles ensure uniform delivery over the area of targeted tissue.
In one embodiment of the device of the present invention, a sheath (see Figure 5) surrounding at least a part of the balloon is included. The sheath of the present invention can be made from various materials, for example, metals, such as nitinol, platinum, stainless steel, and various alloys, and polymers. Preferably, the sheath is expandable; and the expandable sheath maybe attached to the balloon so that the sheath expands as the balloon expands and collapses as the balloon is deflated.
Furthermore, the sheath has a plurality of ports. The ports can be any shape, such as a round, oval or square hole and a slit, so long as the micro-needles can project through the ports. The sheath can also be formed of a mesh. Generally, the thickness of the sheath is between about 0.01 and about 0.1 mm.
Alternatively, a sheath without ports may be made of a material which is capable of being punctured by the micro-needles, such as a polymer. When the balloon is inflated, the micro-needles disposed upon the balloon puncture the sheath and project through the sheath. Examples of polymers suitable for the sheath are polyurethanes, polyesters, PTFE and FEP; polyethylene and nylon are preferable. One of ordinary skill can select the polymer material and thickness for the sheath as well as the material and sizes of the needles in order to obtain the desired results.
Moreover, another embodiment of the device of the present invention involves a Shockwave generator for delivery of the biologically active material to the body lumen (see Figures 6 A and 6B). Shockwave sources known in the art can be used for the present invention; preferably the source generates a Shockwave having enough energy to disrupt the cell lipid bilayer of the cells in the body lumen. Examples of such sources are disclosed in U.S. Patent No. 5,233,972, U.S. Patent No. 5,374,236, and U.S. Patent No. 4,610,249. Shockwave sources are used extensively in lithotripsy, i.e. methods of treating kidney stones. The same types of sources used in such technique can be applied to the present invention. Generally the energy of the Shockwave used is less intensive than that used in lithotripsy. Also, the area of the body lumen exposed to the Shockwave in the present invention is smaller than that in lithotripsy. To disrupt the cell lipid bilayer, generally, the Shockwave should have a pressure of between about 10 arm and about 5,000 atm, preferably between about 75 atm and about 150 atm pressure are useful. Also, the Shockwave should be applied for relatively short periods of time, such as between about 1 nsec and about 1 msec. hi one embodiment, wherein the biologically active material is contained in a polymer coating on the balloon's exterior surface, when the balloon is positioned and inflated to contact a surface of the body lumen, the Shockwave is created at the proximal portion of the catheter. The Shockwave travels to the distal portion of the catheter where the biologically active material is to be delivered, and disrupts the cell lipid bilayer of the cells in the body lumen. The Shockwave creates a compression force which delivers the biologically active material through the disrupted cell lipid bilayer into the cell cytoplasm. The balloon in this embodiment may also have the micro-needles discussed above.
A balloon catheter of the present invention can be used with a Shockwave source which is not attached to the catheter. When the balloon catheter contacts a surface of
a body lumen, the Shockwave source is focused on the surface from outside the patient's body. Skilled artisans in the art know how to focus on a surface of a body lumen.
In another embodiment of the present invention, the balloon may have micro-needles without any openings but capable of being ruptured as explained above and the micro-needles have an interior lumen in fluid communication with an interior compartment of the balloon, which contains a biologically active material. When the balloon is positioned and inflated, micro-needles contact a surface of the body lumen piercing it. A triggering source is applied to rupture the micro-needles to deliver the biologically active material from the interior compartment.
The description contained herein is for purposes of illustration and not for purposes of limitation. Changes and modifications maybe made to the embodiments of the description and still be within the scope of the invention. Furthermore, obvious changes, modifications or variations will occur to those skilled in the art. Also, all references cited above are incorporated herein, in their entirety, for all purposes related to this disclosure.
Claims
1. An apparatus for delivering a biologically active material to a body lumen, comprising: a catheter having a distal portion and a proximal portion; a balloon, having an outer surface, disposed at the distal portion of the catheter; and a plurality of micro-needles disposed upon the outer surface of the balloon, wherein the micro-needles are capable of contacting the body lumen to deliver the biologically active material to the body lumen; and wherein the micro-needles are selected from the group consisting of inicro-needles having an exterior surface having at least one gutter disposed along the longitudinal axis of the micro-needles to allow the biologically active material to be delivered along the gutter or micro-needles capable of being ruptured.
2. The apparatus of claim 1 , wherein said catheter has a first lumen therethrough; said balloon has an interior compartment which is in fluid communication with the first lumen; and said micro-needles each have a lumen in fluid communication with the interior compartment of the balloon to allow the biologically active material to be delivered through the lumens of the micro-needles to the body lumen.
3. The apparatus of claim 2, wherein the first lumen of the catheter is used for both inflating the balloon and delivering the biologically active material.
4. The apparatus of claim 2, wherein the first lumen is used for delivering the biologically active material, and said catheter has a second lumen for inflating the balloon.
5. The apparatus of claim 2, wherein the balloon further has an inflation compartment for inflating the balloon which is in fluid communication with the inflation lumen.
6. The apparatus of claim 4, wherein said catheter has a third lumen in fluid communication with the interior compartment for delivering a second biologically active material.
7. The apparatus of claim 6, wherein the catheter has a fourth lumen for blood perfusion.
8. The apparatus of claim 2, wherein the interior compartment is used for both inflating the balloon and delivering the biologically active material.
9. An apparatus for delivering a biologically active material to a body lumen, comprising: a catheter having a distal portion and a proximal portion; a balloon, having an outer surface, disposed at the distal portion of the catheter; and a plurality of micro-needles disposed upon the outer surface of the balloon, wherein the micro-needles are capable of contacting the body lumen to deliver the biologically active material to the body lumen, wherein the balloon has an interior compartment for containing the biologically active material, and said micro-needles allow the biologically active material to be delivered through the lumens of the micro-needles to the body lumen.
10. An apparatus for delivering a biologically active material to a body lumen, comprising: a catheter having a distal portion and a proximal portion; a balloon, having an outer surface, disposed at the distal portion of the catheter; and a plurality of micro-needles disposed upon the outer surface of the balloon, wherein the micro-needles are capable of contacting the body lumen to deliver the biologically active material to the body lumen, wherein the outer surface of the balloon is part of a balloon wall and wherein the micro-needles are disposed upon a plate, which is attached to said balloon wall in a manner such that the micro-needles project through the balloon wall.
11. The apparatus of claim 10, wherein the plate is attached to the balloon in a manner such that the micro-needles are capable of being retracted when the balloon is deflated and projected through the balloon wall when the balloon is expanded.
12. The apparatus of claim 9, wherein a second biologically active material is coated onto the outer surface of the balloon.
13. The apparatus of claim 9, wherein the catheter has a first lumen therethrough; wherein the interior compartment is in fluid communication with the first lumen; and wherein the micro-needles each have a lumen in fluid communication with the interior compartment, whereby the biologically active material can be delivered from the interior compartment through the lumens of the micro-needles to the body lumen.
14. The apparatus of claim 9, wherein the outer surface of the balloon is part of a balloon wall and wherein the catheter has a first lumen therethrough; and wherein the balloon has an interior compartment in fluid commumcation with the first lumen, and said balloon wall contains a plurality of pores whereby the biologically active material is delivered to the body lumen through the pores.
15. The apparatus of claim 14, wherein the balloon wall comprises an inner layer and an outer layer, and wherein said plurality of pores are located in the outer layer.
16. The apparatus of claim 15, wherein biologically active material is located between the inner layer and the outer layer.
17. An apparatus for delivering a biologically active material to a body lumen, comprising: a catheter having a distal portion and a proximal portion; a balloon, having an outer surface, disposed at the distal portion of the catheter; and a plurality of micro-needles disposed upon the outer surface of the balloon, a sheath having an inner surface and a plurality of ports, wherein the micro-needles are capable of contacting the body lumen to deliver the biologically active material to the body lumen, and wherein said sheath surrounds the balloon in a manner such that upon expansion of the balloon, an outer surface of the balloon contacts the inner surface of the sheath and the micro-needles project through the ports.
18. The apparatus of claim 17, wherein the sheath is attached to the balloon in a manner such that the sheath expands as the balloon expands and the sheath collapses as the balloon is deflated.
19. The apparatus of claim 17, wherein the micro-needles lay along the outer surface of the balloon when the balloon is in a deflated state, and the micro-needles become erect such that they protrude from the outer surface of the balloon when the balloon is in an expanded state.
20. The apparatus of claim 17, wherein the sheath comprises a plurality of micro- needle channels that are capable of guiding the micro-needles through the ports upon expansion of the balloon.
21. The apparatus of claim 17, wherein the sheath is formed of a mesh material.
22. The apparatus of claim 11, wherein the ports of the sheath are made by being punctured by the micro-needles when the balloon is inflated.
23. A system for delivering a biologically active material to a surface of a body lumen comprising: a catheter having a distal portion and a proximal portion; a balloon, having an outer surface, disposed at the distal portion of the catheter; and a Shockwave generator.
24. The system of claim 23, wherein the Shockwave generator is disposed upon the proximal portion of the catheter.
25. The system of claim 24, wherein the catheter has a first lumen, the balloon has an interior compartment in fluid communication with the first lumen, and wherein the shockwave generator is capable of generating a Shockwave which is propagated through the first lumen and the interior compartment to the body lumen.
26. The system of claim 23, wherein the shockwave generator is located at the exterior of the patient's body and is capable of focusing the shockwave at the body lumen.
27. The system of claim 23, wherein the shockwave generator produces a shockwave having sufficient energy to disrupt a cell lipid bilayer of cells located at the body lumen.
28. The system of claim 23, wherein the shockwave generator produces a shockwave having a pressure between about 10 atm and about 5,000 atm.
29. The system of claim 28, wherein the shockwave generator produces a shockwave having a pressure between about 75 atm and about 150 atm.
30. The system of claim 23, wherein the shockwave generator produces a shockwave lasting for between about 1 nsec and about 1 msec.
31. The system of claim 23, wherein the biologically active material is coated onto an outer surface of the balloon.
32. The system of claim 23, wherein the catheter has a first lumen therethrough, and wherein the balloon has an interior compartment for containing the biologically active material, wherein the interior compartment is in fluid communication with the first lumen, and said balloon outer surface contains a plurality of pores to allow the biologically active material to be delivered through the pores to the body lumen.
33. The system of claim 23, wherein the catheter has a first lumen therethrough; the balloon has an interior compartment which is in fluid communication with the first lumen of the catheter; and wherein a plurality of micro-needles is disposed upon the balloon outer surface and wherein said micro-needles each have a lumen in fluid communication with the interior compartment of the balloon to allow the biologically active material to be delivered through the lumen of the micro-needles to the body lumen.
34. An apparatus for delivering a biologically active material to a body lumen, comprising:
(a) a catheter having a distal portion, a proximal portion and a first lumen therethrough;
(b) a balloon disposed at the distal portion of the catheter and wherein the balloon has an interior compartment in fluid communication with the first lumen of the catheter, and wherein the balloon has an outer surface having a plurality of micro-needles disposed thereon, and wherein said micro-needles have a lumen in fluid communication with the interior compartment and wherein the micro-needles are capable of being ruptured; and
(c) a triggering source, wherein the triggering source ruptures the micro-needles when activated to deliver the biologically active material from the interior compartment of the balloon through the micro-needle lumens to the body lumen.
35. The apparatus of claim 34, wherein the balloon outer surface is part of a balloon wall, and the micro-needles are disposed upon a plate attached to the balloon wall in a manner such that the micro-needles project through the balloon wall.
36. The apparatus of claim 34, wherein the triggering source is disposed at the proximal portion of the catheter.
37. The apparatus of claim 34, wherein the triggering source is selected from the group consisting of a shockwave, ultrasound energy and energy source for delivering a detachable coil.
38. The apparatus of claim 37, wherein the triggering source is a shockwave.
39. A method for delivering a biologically active material to a lumen, comprising the steps of:
(a) inserting a catheter with a balloon disposed thereon into the body lumen, wherein the balloon has an outer surface having a plurality of micro-needles disposed thereon;
(b) inflating the balloon in a manner so that the micro-needles contact the body lumen,
(c) delivering the biologically active material to the body lumen by either
(i) rupturing at least one of the micro-needles each of which has a lumen in fluid connection with an interior compartment which contains the biologically active material (ii) letting the biologically active material coated on the outer surface of the balloon enter the body lumen along gutters on the micro-needles or (iii) letting the biologically active material expelled from an interior compartment of the balloon through pores enter the body lumen through micro- or nano- pores created by piecing the body lumen with the micro-needles.
40. A method for delivering a biologically active material to a body lumen comprising cells having a lipid bilayer, the method comprising the steps of:
(a) inserting a catheter having a balloon disposed thereon for delivering the biologically active material;
(b) inflating the balloon;
(c) applying a shockwave to the body lumen; and
(d) delivering the biologically active material to the body lumen.
41. The method of claim 40, wherein the shockwave disrupts the lipid bilayer of the cells in the body lumen.
42. The method of claim 40, wherein the balloon further comprises a plurality of micro-needles and wherein said micro-needles create micro-or nano-pores upon inflation of the balloon and wherein the biologically active material is delivered to the body lumen through the micro-or nano-pores.
43. The method of claim 40, wherein the biologically active material is contained in a coating disposed upon an outer surface of the balloon.
44. The method of claim 40, wherein the balloon has an outer surface having a plurality of pores, and the balloon comprises an interior compartment for containing the biologically active material and wherein the biologically active material is delivered by expelling the biologically active material from the interior compartment of the balloon through the pores to the body lumen.
45. The method of claim 40, wherein the catheter has a first lumen therethrough; the balloon has an interior compartment for containing a biologically active material which is in fluid communication with the first lumen of the catheter; and where the balloon has an outer surface having a plurality of micro-needles disposed thereon and the micro-needles each have a lumen in fluid communication with the interior compartment; and wherein the biologically active material is delivered by expelling the biologically active material from the interior compartment through the lumens of the micro-needles to the body lumen.
46. The method of claim 40, wherein the shockwave has a pressure between about 10 atm and about 5,000 atm.
47. The method of claim 46, wherein the shockwave has a pressure between about 75 atm and about 150 atm.
48. The method of claim 40, wherein shockwave is applied for between about 1 nsec and about 1 msec.
49. The apparatus of claim 9, wherein the interior compartment containing the biologically active material is not in fluid communication with the catheter.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/724,505 | 2000-11-28 | ||
| US09/724,505 US6638246B1 (en) | 2000-11-28 | 2000-11-28 | Medical device for delivery of a biologically active material to a lumen |
| PCT/US2001/044272 WO2002043796A2 (en) | 2000-11-28 | 2001-11-27 | Balloon catheter having micro-needles on the balloon surface for delivery of a biologically active material to a body lumen |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| AU2002219873C1 AU2002219873C1 (en) | 2002-06-11 |
| AU2002219873A1 true AU2002219873A1 (en) | 2002-08-15 |
| AU2002219873B2 AU2002219873B2 (en) | 2006-08-31 |
| AU2002219873B8 AU2002219873B8 (en) | 2006-11-23 |
Family
ID=24910684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002219873A Ceased AU2002219873B8 (en) | 2000-11-28 | 2001-11-27 | Medical device for delivery of a biologically active material to a lumen |
| AU1987302A Pending AU1987302A (en) | 2000-11-28 | 2001-11-27 | Medical device for delivery of a biologically active material to a lumen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU1987302A Pending AU1987302A (en) | 2000-11-28 | 2001-11-27 | Medical device for delivery of a biologically active material to a lumen |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6638246B1 (en) |
| EP (1) | EP1339448B1 (en) |
| JP (1) | JP4355494B2 (en) |
| AU (2) | AU2002219873B8 (en) |
| CA (1) | CA2430024A1 (en) |
| DE (1) | DE60141284D1 (en) |
| WO (1) | WO2002043796A2 (en) |
Families Citing this family (286)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713297B2 (en) | 1998-04-11 | 2010-05-11 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
| US8177743B2 (en) | 1998-05-18 | 2012-05-15 | Boston Scientific Scimed, Inc. | Localized delivery of drug agents |
| US20020029015A1 (en) * | 2000-07-04 | 2002-03-07 | Edoardo Camenzind | Device for administering a composition in a duct of a human or animal body |
| US6638246B1 (en) * | 2000-11-28 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device for delivery of a biologically active material to a lumen |
| CA2444883A1 (en) * | 2001-04-20 | 2002-10-31 | Alza Corporation | Microprojection array having a beneficial agent containing coating |
| US7488313B2 (en) * | 2001-11-29 | 2009-02-10 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
| US6656155B2 (en) * | 2001-12-17 | 2003-12-02 | Scimed Life Systems, Inc. | Catheter for endoluminal delivery of therapeutic agents that minimizes loss of therapeutic |
| US20040034336A1 (en) * | 2002-08-08 | 2004-02-19 | Neal Scott | Charged liposomes/micelles with encapsulted medical compounds |
| DE10244847A1 (en) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medical device for drug delivery |
| WO2004060471A1 (en) * | 2003-01-02 | 2004-07-22 | Novoste Corporation | Drug delivery balloon catheter |
| US20040267357A1 (en) * | 2003-04-30 | 2004-12-30 | Allen Jeffrey W. | Cardiac valve modification method and device |
| GB0328060D0 (en) * | 2003-12-04 | 2004-01-07 | Sod Conseils Rech Applic | Botulinum toxin treatment |
| US7819822B2 (en) * | 2004-03-06 | 2010-10-26 | Roche Diagnostics Operations, Inc. | Body fluid sampling device |
| KR101198054B1 (en) | 2004-03-06 | 2012-11-06 | 에프. 호프만-라 로슈 아게 | Body fluid sampling device |
| EP3251710A1 (en) | 2004-04-12 | 2017-12-06 | Allergan, Inc. | Multi-site injection system |
| US20150025459A1 (en) * | 2009-07-29 | 2015-01-22 | Allergan, Inc. | Multi-site injection system |
| EP1758633B1 (en) * | 2004-05-13 | 2015-03-18 | Medtronic Vascular, Inc. | Methods for compounding a therapeutic agent to the adventitia of a vessel |
| US20050273049A1 (en) * | 2004-06-08 | 2005-12-08 | Peter Krulevitch | Drug delivery device using microprojections |
| JP2005349202A (en) * | 2004-06-08 | 2005-12-22 | Cordis Corp | Instrument and method for delivering therapeutic agent into tissue |
| US20060190022A1 (en) * | 2004-07-14 | 2006-08-24 | By-Pass, Inc. | Material delivery system |
| US20060100584A1 (en) * | 2004-08-10 | 2006-05-11 | Orest Olejnik | Needleless microprotrusion elastoplast system |
| AR050608A1 (en) * | 2004-08-19 | 2006-11-08 | Alza Corp | APPARATUS AND METHOD FOR TRANSDERMAL ADMINISTRATION OF VASCULAR ENDOTELIAL GROWTH FACTORS |
| US7470252B2 (en) * | 2004-09-16 | 2008-12-30 | Boston Scientific Scimed, Inc. | Expandable multi-port therapeutic delivery system |
| US8750983B2 (en) | 2004-09-20 | 2014-06-10 | P Tech, Llc | Therapeutic system |
| KR20070100820A (en) | 2005-01-31 | 2007-10-11 | 가부시키가이샤 바이오세렌택 | Percutaneous Absorbent Formulations, Transdermal Absorbent Formulation Retention Sheets and Percutaneous Absorbent Retention Agent |
| CN100450563C (en) * | 2005-01-31 | 2009-01-14 | 重庆海扶(Hifu)技术有限公司 | Device for delivering medium to body cavity, vascular-cavity leading-in and ultrasonic blocking |
| US7850645B2 (en) * | 2005-02-11 | 2010-12-14 | Boston Scientific Scimed, Inc. | Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power |
| US8280476B2 (en) * | 2005-03-29 | 2012-10-02 | Arkal Medical, Inc. | Devices, systems, methods and tools for continuous glucose monitoring |
| AU2006255043B2 (en) * | 2005-06-07 | 2013-01-17 | David R. Staskin | Injection guidance system and method |
| US20070066934A1 (en) * | 2005-09-19 | 2007-03-22 | Transport Pharmaceuticals, Inc. | Electrokinetic delivery system and methods therefor |
| RU2290936C1 (en) * | 2006-01-31 | 2007-01-10 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Method for preparing agent for maintaining therapy possessing tissue-specific activity |
| US20070191811A1 (en) * | 2006-02-10 | 2007-08-16 | Joseph Berglund | System and Method for Treating a Vascular Condition |
| US20070191766A1 (en) * | 2006-02-10 | 2007-08-16 | Boston Scientific Scimed, Inc. | Balloon catheter having nanotubes |
| ES2335520T3 (en) * | 2006-02-24 | 2010-03-29 | National University Of Ireland, Galway | MINIMALLY INVASIVE INTRAVASCULAR TREATMENT DEVICE. |
| US20080077165A1 (en) * | 2006-02-24 | 2008-03-27 | National University Of Ireland, Galway | Minimally Invasive Intravascular Treatment Device |
| US20080077164A1 (en) * | 2006-02-24 | 2008-03-27 | National University Of Ireland, Galway | Minimally Invasive Intravascular Treatment Device |
| US20070224235A1 (en) | 2006-03-24 | 2007-09-27 | Barron Tenney | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
| US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
| US20090131778A1 (en) * | 2006-03-28 | 2009-05-21 | Jina Arvind N | Devices, systems, methods and tools for continuous glucose monitoring |
| US20100049021A1 (en) * | 2006-03-28 | 2010-02-25 | Jina Arvind N | Devices, systems, methods and tools for continuous analyte monitoring |
| US20080154107A1 (en) * | 2006-12-20 | 2008-06-26 | Jina Arvind N | Device, systems, methods and tools for continuous glucose monitoring |
| US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
| JP2009542359A (en) | 2006-06-29 | 2009-12-03 | ボストン サイエンティフィック リミテッド | Medical device with selective covering |
| US20080058726A1 (en) * | 2006-08-30 | 2008-03-06 | Arvind Jina | Methods and Apparatus Incorporating a Surface Penetration Device |
| US20080097297A1 (en) * | 2006-08-31 | 2008-04-24 | Kelley Gregory S | Medical device for local site-specific drug delivery |
| ATE508708T1 (en) | 2006-09-14 | 2011-05-15 | Boston Scient Ltd | MEDICAL DEVICES WITH A DRUG-RELEASING COATING |
| US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
| US9232959B2 (en) | 2007-01-02 | 2016-01-12 | Aquabeam, Llc | Multi fluid tissue resection methods and devices |
| US12290277B2 (en) | 2007-01-02 | 2025-05-06 | Aquabeam, Llc | Tissue resection with pressure sensing |
| NZ588816A (en) | 2007-01-21 | 2011-11-25 | Hemoteq Ag | Medical device for the treatment of stenoses of corporal lumina and for the prevention of impending restenoses |
| DE102007003184A1 (en) | 2007-01-22 | 2008-07-24 | Orlowski, Michael, Dr. | Method for loading structured surfaces |
| US8070797B2 (en) | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
| US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
| WO2008106806A1 (en) * | 2007-03-02 | 2008-09-12 | Tecpharma Licensing Ag | Modular administration system |
| US20080234562A1 (en) * | 2007-03-19 | 2008-09-25 | Jina Arvind N | Continuous analyte monitor with multi-point self-calibration |
| US8067054B2 (en) | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
| US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
| US20080300610A1 (en) * | 2007-05-31 | 2008-12-04 | Cook Incorporated | Device for treating hardened lesions and method of use thereof |
| US20080312518A1 (en) * | 2007-06-14 | 2008-12-18 | Arkal Medical, Inc | On-demand analyte monitor and method of use |
| US8109904B1 (en) | 2007-06-25 | 2012-02-07 | Abbott Cardiovascular Systems Inc. | Drug delivery medical devices |
| US9370642B2 (en) * | 2007-06-29 | 2016-06-21 | J.W. Medical Systems Ltd. | Adjustable-length drug delivery balloon |
| US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
| US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
| US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
| JP2010533563A (en) | 2007-07-19 | 2010-10-28 | ボストン サイエンティフィック リミテッド | Endoprosthesis with adsorption inhibiting surface |
| US7931683B2 (en) | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
| US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
| US8221822B2 (en) | 2007-07-31 | 2012-07-17 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
| WO2009020520A1 (en) | 2007-08-03 | 2009-02-12 | Boston Scientific Scimed, Inc. | Coating for medical device having increased surface area |
| US8556880B2 (en) | 2007-09-06 | 2013-10-15 | Boston Scientific Scimed, Inc. | Methods and devices for local therapeutic agent delivery to heart valves |
| US8579956B2 (en) * | 2007-09-28 | 2013-11-12 | Abbott Cardiovascular Systems Inc. | Methods and devices for treating lesions |
| US20090099427A1 (en) * | 2007-10-12 | 2009-04-16 | Arkal Medical, Inc. | Microneedle array with diverse needle configurations |
| US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
| US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
| US7938855B2 (en) | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
| CA2705709C (en) | 2007-11-16 | 2016-03-15 | Synthes Usa, Llc | Porous containment device and associated method for stabilization of vertebral compression fractures |
| AU2009208930A1 (en) * | 2008-01-31 | 2009-08-06 | Proteon Therapeutics, Inc. | Medical device |
| EP2259742B1 (en) | 2008-03-06 | 2020-01-01 | AquaBeam LLC | Tissue ablation and cautery with optical energy carried in fluid stream |
| EP2594311A3 (en) * | 2008-03-06 | 2013-07-10 | Boston Scientific Scimed, Inc. | Balloon catheter devices with sheath covering |
| US9480826B2 (en) * | 2008-03-21 | 2016-11-01 | Cagent Vascular, Llc | Intravascular device |
| US11219750B2 (en) | 2008-03-21 | 2022-01-11 | Cagent Vascular, Inc. | System and method for plaque serration |
| CA2718067C (en) | 2008-03-21 | 2014-07-08 | Innovasc Llc | Device and method for opening blood vessels by pre-angioplasty serration and dilatation of atherosclerotic plaque |
| WO2009120361A2 (en) * | 2008-03-28 | 2009-10-01 | Surmodics, Inc. | Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery |
| ES2423504T3 (en) | 2008-04-22 | 2013-09-20 | Boston Scientific Scimed, Inc. | Medical devices that have a coating of inorganic material |
| WO2009132176A2 (en) | 2008-04-24 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
| US20100036294A1 (en) | 2008-05-07 | 2010-02-11 | Robert Mantell | Radially-Firing Electrohydraulic Lithotripsy Probe |
| US9072534B2 (en) | 2008-06-13 | 2015-07-07 | Shockwave Medical, Inc. | Non-cavitation shockwave balloon catheter system |
| CA2727429C (en) | 2008-06-13 | 2016-01-26 | Daniel Hawkins | Shockwave balloon catheter system |
| US10702293B2 (en) | 2008-06-13 | 2020-07-07 | Shockwave Medical, Inc. | Two-stage method for treating calcified lesions within the wall of a blood vessel |
| WO2009155328A2 (en) | 2008-06-18 | 2009-12-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
| US20100016862A1 (en) * | 2008-07-16 | 2010-01-21 | Daniel Hawkins | Method of providing embolic protection and shockwave angioplasty therapy to a vessel |
| WO2010011930A2 (en) * | 2008-07-24 | 2010-01-28 | Boston Scientific Scimed, Inc. | Various catheter devices for myocardial injections or other uses |
| US9295820B2 (en) | 2008-08-14 | 2016-03-29 | Surmodics, Inc. | Method and apparatus for coating balloon catheters |
| EP2328650B1 (en) | 2008-08-26 | 2016-04-06 | Cook Medical Technologies LLC | Balloon catheters having a plurality of needles for the injection of one or more therapeutic agents |
| US20100081873A1 (en) * | 2008-09-30 | 2010-04-01 | AiHeart Medical Technologies, Inc. | Systems and methods for optical viewing and therapeutic intervention in blood vessels |
| EP2172242A1 (en) * | 2008-10-03 | 2010-04-07 | National University of Ireland Galway | Intravascular Treatment Device |
| US9180280B2 (en) * | 2008-11-04 | 2015-11-10 | Shockwave Medical, Inc. | Drug delivery shockwave balloon catheter system |
| US9044618B2 (en) | 2008-11-05 | 2015-06-02 | Shockwave Medical, Inc. | Shockwave valvuloplasty catheter system |
| US8540667B2 (en) * | 2008-11-12 | 2013-09-24 | Sanovas, Inc. | Multi-balloon catheter for extravasated drug delivery |
| US8226601B2 (en) | 2008-11-12 | 2012-07-24 | Sanovas, Inc. | Resector balloon system |
| US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
| US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
| CN102448393A (en) | 2009-04-09 | 2012-05-09 | 斯恩蒂斯有限公司 | Minimally invasive spine augmentation and stabilization system and method |
| US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
| EP2243501A1 (en) | 2009-04-24 | 2010-10-27 | Eurocor Gmbh | Shellac and paclitaxel coated catheter balloons |
| DE202009006632U1 (en) | 2009-05-07 | 2009-07-16 | Sellin, Lothar | Coating of medical surfaces |
| US20100292641A1 (en) * | 2009-05-15 | 2010-11-18 | Bandula Wijay | Targeted drug delivery device and method |
| EP2258439B1 (en) * | 2009-06-04 | 2020-04-29 | Biotronik Ag | Structured drug-eluting balloon catheter |
| EP2451496B1 (en) | 2009-07-10 | 2015-07-22 | Boston Scientific Scimed, Inc. | Use of nanocrystals for a drug delivery balloon |
| JP5933434B2 (en) | 2009-07-17 | 2016-06-08 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Method for producing drug delivery balloon |
| WO2011017335A1 (en) | 2009-08-03 | 2011-02-10 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
| US8764712B2 (en) * | 2009-08-04 | 2014-07-01 | Cook Medical Technologies Llc | Micro-needle array and method of use thereof |
| WO2011028419A1 (en) * | 2009-08-27 | 2011-03-10 | Boston Scientific Scimed, Inc. | Balloon catheter devices with drug-coated sheath |
| US9014799B2 (en) * | 2009-10-08 | 2015-04-21 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including electrically-actuated permeation enhancement |
| US8882748B2 (en) * | 2009-10-08 | 2014-11-11 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including chemical permeation enhancers |
| US9017310B2 (en) * | 2009-10-08 | 2015-04-28 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including microneedles |
| US20120316496A1 (en) | 2009-10-16 | 2012-12-13 | Michael Hoffmann | Use of compositions to coat catheter balloons and coated catheter balloons |
| US8721620B2 (en) | 2009-12-24 | 2014-05-13 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
| US9993625B2 (en) | 2010-01-29 | 2018-06-12 | Mirus Llc | Biodegradable protrusions on inflatable device |
| US8568354B2 (en) | 2010-02-16 | 2013-10-29 | Cardiovascular Systems, Inc. | Devices and methods for low shearing local delivery of therapeutic agents to the wall of a bodily lumen |
| US9050414B2 (en) | 2010-02-19 | 2015-06-09 | Cardiovascular Systems, Inc. | Systems and methods for mixing therapeutic agents before and/or during administration |
| DE102010022588A1 (en) | 2010-05-27 | 2011-12-01 | Hemoteq Ag | Balloon catheter with a particle-free drug-releasing coating |
| WO2012003293A1 (en) | 2010-06-30 | 2012-01-05 | Surmodics, Inc. | Lipid coating for medical devices delivering bioactive agent |
| EP2611476B1 (en) | 2010-09-02 | 2016-08-10 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
| EP2446917A1 (en) * | 2010-10-28 | 2012-05-02 | Biotronik AG | Catheter, system for applying an intraluminal endoprosthesis and method for producing same |
| EP2663356B1 (en) * | 2010-12-16 | 2018-12-12 | Boston Scientific Scimed, Inc. | Micro-needle bladder balloon |
| US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8764733B2 (en) | 2010-12-23 | 2014-07-01 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809271B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US9149617B2 (en) | 2010-12-23 | 2015-10-06 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US20120220861A1 (en) | 2010-12-31 | 2012-08-30 | Volcano Corporation | Multiple Sclerosis Diagnostic Methods and Associated Devices and Systems |
| AU2011200396B2 (en) * | 2011-01-31 | 2015-07-16 | Palo Alto Research Center Incorporated | lntralumenal or intravaginal device for Transmucosal drug delivery |
| US10898693B2 (en) | 2011-03-01 | 2021-01-26 | Sanovas Intellectual Property, Llc | Nasal delivery of agents with nested balloon catheter |
| US8597239B2 (en) | 2011-03-01 | 2013-12-03 | Sanovas, Inc. | Abrading balloon catheter for extravasated drug delivery |
| US8348890B2 (en) * | 2011-03-01 | 2013-01-08 | Sanovas, Inc. | Nested balloon catheter for localized drug delivery |
| US20160074581A1 (en) | 2014-09-17 | 2016-03-17 | Lawrence J. Gerrans | Modulated Drug Delivery |
| US9180281B2 (en) | 2011-04-08 | 2015-11-10 | Sanovas, Inc. | Adjustable balloon catheter for extravasated drug delivery |
| DE102011100122A1 (en) | 2011-04-26 | 2012-10-31 | Eurocor Gmbh | Catheter balloon coated with rapamycin and shellac |
| PL3653223T3 (en) * | 2011-06-29 | 2021-12-20 | Rani Therapeutics, Llc | Device for the oral delivery of therapeutic compounds |
| WO2013007273A1 (en) | 2011-07-08 | 2013-01-17 | Cardionovum Sp.Z.O.O. | Balloon surface coating |
| EP2731661B1 (en) * | 2011-07-12 | 2019-09-18 | Boston Scientific Scimed, Inc. | Drug elution medical device |
| WO2013022458A1 (en) | 2011-08-05 | 2013-02-14 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
| WO2013028208A1 (en) | 2011-08-25 | 2013-02-28 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
| US11357955B2 (en) * | 2011-09-01 | 2022-06-14 | Boston Scientific Scimed, Inc. | Devices, systems, and related methods for delivery of fluid to tissue |
| US9981058B2 (en) | 2011-09-29 | 2018-05-29 | Cardionovum Sp.Z.O.O. | Balloon surface coating |
| US9730726B2 (en) * | 2011-10-07 | 2017-08-15 | W. L. Gore & Associates, Inc. | Balloon assemblies having controllably variable topographies |
| US8574247B2 (en) | 2011-11-08 | 2013-11-05 | Shockwave Medical, Inc. | Shock wave valvuloplasty device with moveable shock wave generator |
| US9504604B2 (en) | 2011-12-16 | 2016-11-29 | Auris Surgical Robotics, Inc. | Lithotripsy eye treatment |
| JP2015077156A (en) * | 2012-01-31 | 2015-04-23 | テルモ株式会社 | In-vivo indwelling object delivery system |
| CN108606773B (en) | 2012-02-29 | 2020-08-11 | 普罗赛普特生物机器人公司 | Automated image-guided tissue resection and processing |
| WO2013134708A1 (en) * | 2012-03-09 | 2013-09-12 | Clearstream Technologies Limited | Medical balloon with a precisely identifiable portion |
| US10383765B2 (en) | 2012-04-24 | 2019-08-20 | Auris Health, Inc. | Apparatus and method for a global coordinate system for use in robotic surgery |
| US9642673B2 (en) | 2012-06-27 | 2017-05-09 | Shockwave Medical, Inc. | Shock wave balloon catheter with multiple shock wave sources |
| WO2014008875A1 (en) | 2012-07-12 | 2014-01-16 | Cardionovum Gmbh | Catheter balloon, method for producing a coated catheter balloon and use of the pharmacological active ingredient |
| CA2881184C (en) | 2012-08-06 | 2019-06-04 | Shockwave Medical, Inc. | Shockwave catheter |
| ES2715678T3 (en) | 2012-08-06 | 2019-06-05 | Shockwave Medical Inc | Low profile electrodes for an angioplasty shock wave catheter |
| JP2015524709A (en) | 2012-08-08 | 2015-08-27 | ショックウェーブ メディカル, インコーポレイテッド | Shock wave valve formation with multiple balloons |
| US9138249B2 (en) | 2012-08-17 | 2015-09-22 | Shockwave Medical, Inc. | Shock wave catheter system with arc preconditioning |
| US9522012B2 (en) | 2012-09-13 | 2016-12-20 | Shockwave Medical, Inc. | Shockwave catheter system with energy control |
| US9333000B2 (en) | 2012-09-13 | 2016-05-10 | Shockwave Medical, Inc. | Shockwave catheter system with energy control |
| US9999720B2 (en) | 2012-09-27 | 2018-06-19 | Palo Alto Research Center Incorporated | Drug reconstitution and delivery device and methods |
| US9005108B2 (en) | 2012-09-27 | 2015-04-14 | Palo Alto Research Center Incorporated | Multiple reservoir drug delivery device and methods |
| US9744341B2 (en) | 2013-01-15 | 2017-08-29 | Palo Alto Research Center Incorporated | Devices and methods for intraluminal retention and drug delivery |
| US10231867B2 (en) | 2013-01-18 | 2019-03-19 | Auris Health, Inc. | Method, apparatus and system for a water jet |
| US9775864B2 (en) * | 2013-01-31 | 2017-10-03 | Ams Research Corporation | Vaginal laxity therapy utilizing cell-based bulking compositions |
| IE20130079A1 (en) | 2013-02-13 | 2014-09-10 | Patrick T Prendergast | Method for loading dilatable catheter balloons and dilatation catheters obtained therefrom |
| JP6071621B2 (en) * | 2013-02-21 | 2017-02-01 | オリンパス株式会社 | Liquid sustained release means, endoscope provided with the same, and endoscopic surgical instrument |
| US9867635B2 (en) | 2013-03-08 | 2018-01-16 | Auris Surgical Robotics, Inc. | Method, apparatus and system for a water jet |
| US10149720B2 (en) | 2013-03-08 | 2018-12-11 | Auris Health, Inc. | Method, apparatus, and a system for facilitating bending of an instrument in a surgical or medical robotic environment |
| US10080576B2 (en) | 2013-03-08 | 2018-09-25 | Auris Health, Inc. | Method, apparatus, and a system for facilitating bending of an instrument in a surgical or medical robotic environment |
| ES2703539T3 (en) | 2013-03-11 | 2019-03-11 | Northgate Tech Inc | Unfocused electrohydraulic lithotripter |
| US9108030B2 (en) * | 2013-03-14 | 2015-08-18 | Covidien Lp | Fluid delivery catheter with pressure-actuating needle deployment and retraction |
| WO2014177221A1 (en) | 2013-05-02 | 2014-11-06 | Cardionovum Gmbh | Balloon surface coating |
| WO2014201165A1 (en) | 2013-06-11 | 2014-12-18 | Auris Surgical Robotics, Inc. | System for robotic assisted cataract surgery |
| US10426661B2 (en) | 2013-08-13 | 2019-10-01 | Auris Health, Inc. | Method and apparatus for laser assisted cataract surgery |
| US9539041B2 (en) | 2013-09-12 | 2017-01-10 | DePuy Synthes Products, Inc. | Minimally invasive biomaterial injection system |
| KR102332023B1 (en) | 2013-10-24 | 2021-12-01 | 아우리스 헬스, 인크. | System for Robotic-Assisted Endolumenal Surgery and Related Methods |
| US9980785B2 (en) | 2013-10-24 | 2018-05-29 | Auris Health, Inc. | Instrument device manipulator with surgical tool de-articulation |
| US9297083B2 (en) | 2013-12-16 | 2016-03-29 | Palo Alto Research Center Incorporated | Electrolytic gas generating devices, actuators, and methods |
| KR101493327B1 (en) * | 2014-02-28 | 2015-02-16 | 연세대학교 산학협력단 | Balloon Catheter Having Micro Needles and Manufacturing Method Thereof |
| EP3132822B1 (en) * | 2014-04-14 | 2018-10-31 | Toppan Printing Co., Ltd. | Injection device |
| US9730715B2 (en) | 2014-05-08 | 2017-08-15 | Shockwave Medical, Inc. | Shock wave guide wire |
| WO2015187872A1 (en) | 2014-06-04 | 2015-12-10 | Cagent Vascular, Llc | Cage for medical balloon |
| US9788910B2 (en) | 2014-07-01 | 2017-10-17 | Auris Surgical Robotics, Inc. | Instrument-mounted tension sensing mechanism for robotically-driven medical instruments |
| US10792464B2 (en) | 2014-07-01 | 2020-10-06 | Auris Health, Inc. | Tool and method for using surgical endoscope with spiral lumens |
| US9801660B2 (en) | 2014-07-31 | 2017-10-31 | Palo Alto Research Center Incorporated | Implantable fluid delivery devices, systems, and methods |
| US10278675B2 (en) | 2014-07-31 | 2019-05-07 | Palo Alto Research Center Incorporated | Implantable estrus detection devices, systems, and methods |
| AU2015343272B2 (en) | 2014-11-03 | 2020-07-16 | Cagent Vascular, Inc. | Serration balloon |
| KR101663805B1 (en) * | 2014-12-03 | 2016-10-14 | 연세대학교 산학협력단 | Balloon Catheter Having Micro Needles and Manufacturing Method Thereof |
| KR101537582B1 (en) * | 2015-01-12 | 2015-07-20 | 연세대학교 산학협력단 | Manufacturing Method for Balloon Catheter Having Micro Needles |
| US10792042B2 (en) * | 2015-01-15 | 2020-10-06 | Ethicon, Inc. | Circular staplers having resorbable microneedles containing active agents |
| JPWO2016158584A1 (en) * | 2015-03-27 | 2018-01-18 | テルモ株式会社 | Dilatation catheter and dilatation catheter manufacturing method |
| JP6524812B2 (en) * | 2015-06-16 | 2019-06-05 | 凸版印刷株式会社 | Microneedle, method of manufacturing microneedle, and method of using microneedle |
| WO2017044884A1 (en) | 2015-09-09 | 2017-03-16 | Auris Surgical Robotics, Inc. | Instrument device manipulator for a surgical robotics system |
| CA2998162A1 (en) | 2015-09-17 | 2017-03-23 | Cagent Vascular, Llc | Wedge dissectors for a medical balloon |
| WO2017087195A1 (en) | 2015-11-18 | 2017-05-26 | Shockwave Medical, Inc. | Shock wave electrodes |
| EP3413964A4 (en) * | 2016-02-08 | 2019-12-04 | Orbusneich Medical Pte. Ltd | DRUG BALLOON |
| US10226265B2 (en) | 2016-04-25 | 2019-03-12 | Shockwave Medical, Inc. | Shock wave device with polarity switching |
| EP3777723B1 (en) | 2016-10-06 | 2024-01-17 | Shockwave Medical, Inc. | Aortic leaflet repair using shock wave applicators |
| WO2018075924A1 (en) * | 2016-10-20 | 2018-04-26 | Retrovascular, Inc. | Method and device for enhanced composition delivery |
| CN110559049B (en) * | 2016-10-27 | 2022-11-08 | 深圳市赛诺思医疗科技有限公司 | Chemical ablation device for treating arrhythmia |
| CN110430915A (en) | 2016-11-02 | 2019-11-08 | 斯特姆普莱特公司 | Methods and devices for delivering cell therapy |
| EP3541464A4 (en) | 2016-11-16 | 2020-07-15 | Cagent Vascular, LLC | SYSTEMS AND METHODS FOR DELIVERING AN ACTIVE SUBSTANCE IN TISSUE BY CUTS |
| US10357264B2 (en) | 2016-12-06 | 2019-07-23 | Shockwave Medical, Inc. | Shock wave balloon catheter with insertable electrodes |
| US10441300B2 (en) | 2017-04-19 | 2019-10-15 | Shockwave Medical, Inc. | Drug delivery shock wave balloon catheter system |
| US11020135B1 (en) | 2017-04-25 | 2021-06-01 | Shockwave Medical, Inc. | Shock wave device for treating vascular plaques |
| US11369574B2 (en) * | 2017-05-17 | 2022-06-28 | Massachusetts Institute Of Technology | Self-righting systems and related components and methods |
| US11541015B2 (en) | 2017-05-17 | 2023-01-03 | Massachusetts Institute Of Technology | Self-righting systems, methods, and related components |
| US10966737B2 (en) | 2017-06-19 | 2021-04-06 | Shockwave Medical, Inc. | Device and method for generating forward directed shock waves |
| EP3690015A4 (en) * | 2017-09-29 | 2020-11-18 | Toppan Printing Co., Ltd. | CELL TRANSPLANT DEVICE AND CELL TRANSPLANT UNIT |
| US10709462B2 (en) | 2017-11-17 | 2020-07-14 | Shockwave Medical, Inc. | Low profile electrodes for a shock wave catheter |
| US10918839B2 (en) * | 2018-03-13 | 2021-02-16 | II Jaro Mayda | Balloon catheter |
| US11318288B2 (en) | 2018-03-27 | 2022-05-03 | Gyrus Acmi, Inc. | Instrument for delivering substances into the anatomy |
| AU2019269636A1 (en) | 2018-05-17 | 2020-11-19 | Massachusetts Institute Of Technology | Systems for electrical stimulation |
| US11819229B2 (en) | 2019-06-19 | 2023-11-21 | Boston Scientific Scimed, Inc. | Balloon surface photoacoustic pressure wave generation to disrupt vascular lesions |
| JP7280897B2 (en) | 2018-06-21 | 2023-05-24 | ショックウェーブ メディカル, インコーポレイテッド | System for treating an obstruction within a body lumen |
| WO2020023749A1 (en) | 2018-07-25 | 2020-01-30 | Cagent Vascular, Llc | Medical balloon catheters with enhanced pushability |
| JP7203321B2 (en) * | 2018-08-14 | 2023-01-13 | 福岡県 | Method for manufacturing microneedle array |
| KR102047610B1 (en) * | 2018-12-18 | 2019-11-22 | 이민우 | Micro Needle Device with Multi Mini-Injection Part |
| JP2022523121A (en) | 2019-02-01 | 2022-04-21 | マサチューセッツ インスティテュート オブ テクノロジー | Systems and methods for liquid injection |
| CN110193133B (en) * | 2019-05-24 | 2023-06-06 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | A bladder drug injection device |
| US12402946B2 (en) | 2019-06-19 | 2025-09-02 | Boston Scientific Scimed, Inc. | Breakdown of laser pulse energy for breakup of vascular calcium |
| US11717139B2 (en) | 2019-06-19 | 2023-08-08 | Bolt Medical, Inc. | Plasma creation via nonaqueous optical breakdown of laser pulse energy for breakup of vascular calcium |
| US11660427B2 (en) | 2019-06-24 | 2023-05-30 | Boston Scientific Scimed, Inc. | Superheating system for inertial impulse generation to disrupt vascular lesions |
| US11517713B2 (en) | 2019-06-26 | 2022-12-06 | Boston Scientific Scimed, Inc. | Light guide protection structures for plasma system to disrupt vascular lesions |
| US11478261B2 (en) | 2019-09-24 | 2022-10-25 | Shockwave Medical, Inc. | System for treating thrombus in body lumens |
| US12426938B2 (en) | 2019-09-24 | 2025-09-30 | Shockwave Medical, Inc. | Low profile electrodes for a shock wave catheter |
| AU2020354360A1 (en) | 2019-09-24 | 2022-04-07 | Shockwave Medical, Inc. | Lesion crossing shock wave catheter |
| US11583339B2 (en) | 2019-10-31 | 2023-02-21 | Bolt Medical, Inc. | Asymmetrical balloon for intravascular lithotripsy device and method |
| US12102384B2 (en) | 2019-11-13 | 2024-10-01 | Bolt Medical, Inc. | Dynamic intravascular lithotripsy device with movable energy guide |
| US11541216B2 (en) | 2019-11-21 | 2023-01-03 | Massachusetts Institute Of Technology | Methods for manufacturing tissue interfacing components |
| US12274497B2 (en) | 2019-12-18 | 2025-04-15 | Bolt Medical, Inc. | Multiplexer for laser-driven intravascular lithotripsy device |
| CA3168819A1 (en) | 2019-12-24 | 2021-07-01 | Encompass Vascular, Inc. | Medical devices for fluid delivery |
| US12446961B2 (en) | 2020-02-10 | 2025-10-21 | Bolt Medical, Inc. | System and method for pressure monitoring within a catheter system |
| US11672599B2 (en) | 2020-03-09 | 2023-06-13 | Bolt Medical, Inc. | Acoustic performance monitoring system and method within intravascular lithotripsy device |
| US20210290286A1 (en) | 2020-03-18 | 2021-09-23 | Bolt Medical, Inc. | Optical analyzer assembly and method for intravascular lithotripsy device |
| US11707323B2 (en) | 2020-04-03 | 2023-07-25 | Bolt Medical, Inc. | Electrical analyzer assembly for intravascular lithotripsy device |
| US12295654B2 (en) | 2020-06-03 | 2025-05-13 | Boston Scientific Scimed, Inc. | System and method for maintaining balloon integrity within intravascular lithotripsy device with plasma generator |
| US12207870B2 (en) | 2020-06-15 | 2025-01-28 | Boston Scientific Scimed, Inc. | Spectroscopic tissue identification for balloon intravascular lithotripsy guidance |
| WO2022024074A1 (en) * | 2020-07-31 | 2022-02-03 | King Abdullah University Of Science And Technology | Microneedle balloon catheter |
| EP4199798A1 (en) * | 2020-09-27 | 2023-06-28 | Boston Scientific Scimed Inc. | Expandable guide devices, systems, and methods |
| US11992232B2 (en) | 2020-10-27 | 2024-05-28 | Shockwave Medical, Inc. | System for treating thrombus in body lumens |
| US12232755B2 (en) | 2020-12-11 | 2025-02-25 | Shockwave Medical, Inc. | Lesion crossing shock wave catheter |
| US12016610B2 (en) | 2020-12-11 | 2024-06-25 | Bolt Medical, Inc. | Catheter system for valvuloplasty procedure |
| US11672585B2 (en) | 2021-01-12 | 2023-06-13 | Bolt Medical, Inc. | Balloon assembly for valvuloplasty catheter system |
| WO2022154954A1 (en) | 2021-01-12 | 2022-07-21 | Bolt Medical, Inc. | Balloon assembly for valvuloplasty catheter system |
| EP4297837A4 (en) | 2021-02-23 | 2025-01-15 | Encompass Vascular, Inc. | MEDICAL DEVICES FOR FLUID DELIVERY AND METHODS OF USE AND MANUFACTURE |
| CN113117220B (en) * | 2021-04-14 | 2023-03-21 | 深圳市赛禾医疗技术有限公司 | Medicine balloon catheter, medicine balloon catheter system and control method thereof |
| EP4329855A4 (en) | 2021-04-30 | 2025-03-26 | Encompass Vascular, Inc. | Medical devices for fluid delivery and methods of use and manufacture |
| EP4085855A1 (en) * | 2021-05-04 | 2022-11-09 | Hemosquid | Hemostatic device |
| EP4333746A1 (en) * | 2021-05-04 | 2024-03-13 | Hemosquid | Hemostatic device |
| US11648057B2 (en) | 2021-05-10 | 2023-05-16 | Bolt Medical, Inc. | Optical analyzer assembly with safety shutdown system for intravascular lithotripsy device |
| US11806075B2 (en) | 2021-06-07 | 2023-11-07 | Bolt Medical, Inc. | Active alignment system and method for laser optical coupling |
| US12089861B2 (en) | 2021-08-05 | 2024-09-17 | Nextern Innovation, Llc | Intravascular lithotripsy system and device |
| US11896248B2 (en) | 2021-08-05 | 2024-02-13 | Nextern Innovation, Llc | Systems, devices and methods for generating subsonic pressure waves in intravascular lithotripsy |
| US11957369B2 (en) | 2021-08-05 | 2024-04-16 | Nextern Innovation, Llc | Intravascular lithotripsy systems and methods |
| US11801066B2 (en) | 2021-08-05 | 2023-10-31 | Nextern Innovation, Llc | Systems, devices and methods for selection of arc location within a lithoplasty balloon spark gap |
| US11877761B2 (en) | 2021-08-05 | 2024-01-23 | Nextern Innovation, Llc | Systems, devices and methods for monitoring voltage and current and controlling voltage of voltage pulse generators |
| US12023098B2 (en) | 2021-10-05 | 2024-07-02 | Shockwave Medical, Inc. | Lesion crossing shock wave catheter |
| US11839391B2 (en) | 2021-12-14 | 2023-12-12 | Bolt Medical, Inc. | Optical emitter housing assembly for intravascular lithotripsy device |
| KR102857955B1 (en) | 2022-04-06 | 2025-09-11 | 서울대학교산학협력단 | Drug delivery device |
| US12290268B2 (en) | 2023-03-31 | 2025-05-06 | Shockwave Medical, Inc. | Shockwave catheters for treating rhinosinusitis |
| CN116328159B (en) * | 2023-04-10 | 2025-12-05 | 苏州天鸿盛捷医疗器械有限公司 | A balloon catheter with microneedles and its preparation method |
| US12035932B1 (en) | 2023-04-21 | 2024-07-16 | Shockwave Medical, Inc. | Intravascular lithotripsy catheter with slotted emitter bands |
| US12220141B2 (en) | 2023-06-29 | 2025-02-11 | Shockwave Medical, Inc. | Catheter system with independently controllable bubble and arc generation |
| US12496078B2 (en) | 2023-08-24 | 2025-12-16 | Shockwave Medical, Inc. | Lithotripsy catheters having electrodes formed in metallization layers |
| US12426904B2 (en) | 2023-11-17 | 2025-09-30 | Shockwave Medical, Inc. | Intravascular lithotripsy catheter with oscillating impactor |
| US12402899B2 (en) | 2023-11-30 | 2025-09-02 | Shockwave Medical, Inc. | Systems, devices, and methods for generating shock waves in a forward direction |
| US12396742B1 (en) | 2024-02-08 | 2025-08-26 | IV-X Medical, LLC | Intravascular lithotripsy system |
| US12433620B2 (en) | 2024-02-23 | 2025-10-07 | Shockwave Medical, Inc. | Locus emitter shock wave catheter devices with increased longevity and higher sonic output |
| US12471939B2 (en) | 2024-03-05 | 2025-11-18 | Shockwave Medical, Inc. | Shock wave catheter with retractable enclosure |
| US12178458B1 (en) | 2024-05-16 | 2024-12-31 | Shockwave Medical, Inc. | Guidewireless shock wave catheters |
| US12453565B1 (en) | 2024-11-18 | 2025-10-28 | Shockwave Medical, Inc. | Shock wave catheters and methods of use thereof for treating, imaging, and characterizing body lumens |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4610249A (en) | 1984-05-08 | 1986-09-09 | The Johns Hopkins University | Means and method for the noninvasive fragmentation of body concretions |
| US4796629A (en) | 1987-06-03 | 1989-01-10 | Joseph Grayzel | Stiffened dilation balloon catheter device |
| US5336188A (en) * | 1989-06-16 | 1994-08-09 | Science Incorporated | Fluid delivery apparatus having a stored energy source |
| HU212760B (en) * | 1989-06-20 | 1997-02-28 | Denes | Method and device for the apportion of chemical materials into the vein wall |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
| US5569245A (en) | 1990-03-13 | 1996-10-29 | The Regents Of The University Of California | Detachable endovascular occlusion device activated by alternating electric current |
| US5120322A (en) | 1990-06-13 | 1992-06-09 | Lathrotec, Inc. | Method and apparatus for treatment of fibrotic lesions |
| US5320634A (en) * | 1990-07-03 | 1994-06-14 | Interventional Technologies, Inc. | Balloon catheter with seated cutting edges |
| US5233972A (en) | 1990-09-27 | 1993-08-10 | Siemens Aktiengesellschaft | Shockwave source for acoustic shockwaves |
| US5102402A (en) | 1991-01-04 | 1992-04-07 | Medtronic, Inc. | Releasable coatings on balloon catheters |
| JPH04282146A (en) | 1991-03-08 | 1992-10-07 | Fujikura Ltd | Endoscope catheter |
| DE4110102A1 (en) | 1991-03-27 | 1992-10-01 | Siemens Ag | ELECTROMAGNETIC PRESSURE PULSE SOURCE |
| US5102132A (en) | 1991-04-23 | 1992-04-07 | Dennis Chen | Protective assembly for tennis rackets |
| US5154725A (en) | 1991-06-07 | 1992-10-13 | Advanced Cardiovascular Systems, Inc. | Easily exchangeable catheter system |
| DE4235506A1 (en) * | 1992-10-21 | 1994-04-28 | Bavaria Med Tech | Drug injection catheter |
| DK1293559T3 (en) | 1994-01-21 | 2005-11-28 | Powderject Vaccines Inc | Gas-powered re-entry instrument |
| EP0707942B1 (en) | 1994-10-20 | 2000-03-01 | Interventional Technologies Inc | Method for manufacturing a polymeric material with enhanced mechanical properties |
| US6210356B1 (en) | 1998-08-05 | 2001-04-03 | Ekos Corporation | Ultrasound assembly for use with a catheter |
| US5713863A (en) | 1996-01-11 | 1998-02-03 | Interventional Technologies Inc. | Catheter with fluid medication injectors |
| US6102904A (en) | 1995-07-10 | 2000-08-15 | Interventional Technologies, Inc. | Device for injecting fluid into a wall of a blood vessel |
| US5746716A (en) | 1995-07-10 | 1998-05-05 | Interventional Technologies Inc. | Catheter for injecting fluid medication into an arterial wall |
| US5873852A (en) | 1995-07-10 | 1999-02-23 | Interventional Technologies | Device for injecting fluid into a wall of a blood vessel |
| US5693029A (en) * | 1995-07-10 | 1997-12-02 | World Medical Manufacturing Corporation | Pro-cell intra-cavity therapeutic agent delivery device |
| DE19525607A1 (en) | 1995-07-14 | 1997-01-16 | Boehringer Ingelheim Kg | Transcorneal drug delivery system |
| JPH0928665A (en) | 1995-07-21 | 1997-02-04 | Terumo Corp | Catheter |
| US5725494A (en) | 1995-11-30 | 1998-03-10 | Pharmasonics, Inc. | Apparatus and methods for ultrasonically enhanced intraluminal therapy |
| WO1997023256A1 (en) * | 1995-12-22 | 1997-07-03 | Localmed, Inc. | Localized intravascular delivery of growth factors for promotion of angiogenesis |
| US6197013B1 (en) | 1996-11-06 | 2001-03-06 | Setagon, Inc. | Method and apparatus for drug and gene delivery |
| WO1998048711A1 (en) | 1997-05-01 | 1998-11-05 | Ekos Corporation | Ultrasound catheter |
| US6723063B1 (en) | 1998-06-29 | 2004-04-20 | Ekos Corporation | Sheath for use with an ultrasound element |
| JP4441000B2 (en) | 1997-06-23 | 2010-03-24 | 克郎 立花 | Biological tissue processing device |
| US6210393B1 (en) | 1997-12-31 | 2001-04-03 | Pharmasonics, Inc. | Methods and systems for the inhibition of vascular hyperplasia |
| JPH11225985A (en) | 1998-02-16 | 1999-08-24 | Toshiba Corp | MRI probe |
| US6503231B1 (en) * | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| JP2002517300A (en) | 1998-06-10 | 2002-06-18 | ジョージア テック リサーチ コーポレイション | Microneedle devices and methods of manufacture and uses thereof |
| US6312402B1 (en) | 1998-09-24 | 2001-11-06 | Ekos Corporation | Ultrasound catheter for improving blood flow to the heart |
| US6135976A (en) * | 1998-09-25 | 2000-10-24 | Ekos Corporation | Method, device and kit for performing gene therapy |
| US6210392B1 (en) * | 1999-01-15 | 2001-04-03 | Interventional Technologies, Inc. | Method for treating a wall of a blood vessel |
| US6302870B1 (en) | 1999-04-29 | 2001-10-16 | Precision Vascular Systems, Inc. | Apparatus for injecting fluids into the walls of blood vessels, body cavities, and the like |
| US6689103B1 (en) * | 1999-05-07 | 2004-02-10 | Scimed Life System, Inc. | Injection array apparatus and method |
| US6565532B1 (en) * | 2000-07-12 | 2003-05-20 | The Procter & Gamble Company | Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup |
| US6638246B1 (en) * | 2000-11-28 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device for delivery of a biologically active material to a lumen |
-
2000
- 2000-11-28 US US09/724,505 patent/US6638246B1/en not_active Expired - Lifetime
-
2001
- 2001-11-27 DE DE60141284T patent/DE60141284D1/en not_active Expired - Lifetime
- 2001-11-27 CA CA002430024A patent/CA2430024A1/en not_active Abandoned
- 2001-11-27 AU AU2002219873A patent/AU2002219873B8/en not_active Ceased
- 2001-11-27 EP EP01998374A patent/EP1339448B1/en not_active Expired - Lifetime
- 2001-11-27 JP JP2002545765A patent/JP4355494B2/en not_active Expired - Fee Related
- 2001-11-27 WO PCT/US2001/044272 patent/WO2002043796A2/en not_active Ceased
- 2001-11-27 AU AU1987302A patent/AU1987302A/en active Pending
-
2003
- 2003-08-20 US US10/645,652 patent/US7569032B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002219873B8 (en) | Medical device for delivery of a biologically active material to a lumen | |
| AU2002219873A1 (en) | Medical device for delivery of a biologically active material to a lumen | |
| EP1663374B1 (en) | Medical device with drug delivery member | |
| US20090105687A1 (en) | Scoring catheter with drug delivery membrane | |
| US6692466B1 (en) | Drug delivery catheter with retractable needle | |
| EP1441784B1 (en) | Medical device for delivering patches | |
| US7967836B2 (en) | Dilatation balloon having reduced rigidity | |
| US20050273049A1 (en) | Drug delivery device using microprojections | |
| US20050273075A1 (en) | Method for delivering drugs to the adventitia using device having microprojections | |
| US6706013B1 (en) | Variable length drug delivery catheter | |
| US20130204179A1 (en) | Methods and Systems for Delivering Substances Into Luminal Walls | |
| JP2005349202A (en) | Instrument and method for delivering therapeutic agent into tissue | |
| HK1084056A (en) | Drug delivery device using microprojections |